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Abstract. – OBJECTIVE: Bipolar disorder 
(BD) is a severe disorder, and it is associated 
with an increased risk of mortality. About 25% 
of patients with BD have attempted and 11% 
have died by suicide. All these characteristics 
suggest that the disorders within the bipolar 
spectrum are a crucial public health problem. 
With the development of molecular genetics in 
recent decades, it was possible to more easi-
ly detect risk genes associated with this disor-
der. This study aimed at summarizing the find-
ings of systematic reviews and meta-analyses 
on the topic and assessing the quality of the 
available evidence. 
MATERIALS AND METHODS: PubMed/Med-
line and Web of Science were searched to iden-
tify systematic reviews and meta-analyses pub-
lished during 2013-2019. Standard methodology 
was applied to synthesize and assess the re-
trieved literature.
RESULTS: This systematic review identifies a 
number of potential risk genes associated with 
bipolar disorder whose mechanism of action 
has yet to be confirmed. They are divided into 
several groups: 1) a list of the most significant 
susceptibility genetic factors associated with 
BD; 2) the implication of the ZNF804A gene in 
BD; 3) the role of genes involved in calcium sig-
naling in BD; 4) DNA methylation in BD; 5) BD 
and risk suicide genes; 6) susceptibility genes 
for early-onset BD; 7) candidate genes common 
to both BD and schizophrenia; 8) genes involved 
in cognitive status in BD cases; 9) genes in-
volved in structural alteration in BD brain tissue; 
10) genes involved in lithium response in BD.
CONCLUSIONS: Future research should con-
centrate on molecular mechanisms by which 
genetic variants play a major role in BD. Sup-
plemental research is needed to replicate the 
applicable results.
Key Words: 
Bipolar disorder, Genes, Gene regions, Ge-
nome-wide association, Genomic mutations, Chromo-
some.
Introduction 
Bipolar disorder involves a very heavy burden 
of suffering for those who are affected by it, for 
its family members and the environment that sur-
rounds it. BD causes unusual changes in the per-
son’s mood, energy and the capacity to function1. 
The clinical history of the disease may present ep-
isodes from mild depression and transitory hypo-
mania to critical psychotic mania or depression. 
The elevated rates of delayed or mistaken diag-
nosis reported by bipolar patients imply that there 
is still a huge gap between the available knowl-
edge of BD and its implementation in the clini-
cal setting. There are still controversies related to 
the identification, classification and management 
of this condition2. It is widely accepted that bipo-
lar disease is often misdiagnosed. An average of 
8.9 years passed between the beginning of symp-
toms and the appropriate diagnosis of BD. One 
of the factors that contribute to this misdiagno-
sis is that patients believe their manic symptoms 
are normal and advantageous. The symptoms can 
also be very inconstant (starting from impulsivity 
behavior, fluctuations in the level of energy and 
substance abuse) and they can mask the BD3. The 
pathophysiology of BD has not been fully clar-
ified because knowledge about the mechanisms 
that contribute to this disease is limited4. Bipolar 
disorder is related to an enhanced risk of mortali-
ty. About 25% of patients have attempted suicide 
and 11% have died by suicide. All these character-
istics suggest that the bipolar spectrum disorder is 
a crucial public health problem5.
The etiology of BD is complex, involving a 
number of independent and interlinked genetic 
factors. Even though the etiology has not yet been 
fully elucidated, a number of studies suggest that 
BD has a strong hereditary basis6. It is estimated 
that the risk of developing BD due to the influence 
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of genetic factors is 60-85%6. Additional clinical 
data show that the risk of beginning and progress-
ing BD in first-degree relatives of patients affected 
by this disease is 5-10 times higher than the preva-
lence in the general population7. With the develop-
ment of molecular genetics in the recent decades, 
it was possible to more easily detect risk genes as-
sociated with BD. However, the method of inher-
itance has not been fully elucidated. For now, the 
disease is thought to be polygenic, inherited from 
a non-Mendelian inheritance model7. The use of 
hypothesis-free genome-wide association studies 
(GWAS) methodology has been on the rise in re-
cent years. Thanks to this methodology, a number 
of risk genetic alleles have been identified in many 
genes associated with BD. Among them, CAC-
NA1C and ANK3 have emerged as one of the most 
significant genetic risk factors involved in BD7.
The purposes of the present systematic review 
are: a) to overview the findings of systematic re-
views and meta-analyses on the association of bi-
polar disorder and potential risk genes; b) to sum-
marize current and available evidence for genes 
and genetic alleles that play a role as a risk fac-
tor in the course and outcome of BD; c) to show 
which genes participate in pathological processes 
that are generated by the disease itself.
Materials and Methods
Recommendations from the Preferred Report-
ing Items for Systematic Reviews and Meta-analy-
ses (PRISMA) guidelines were used in the design, 
organization, and execution of the procedures to 
conduct the search strategy8.
Search Strategy
To identify studies, we searched PubMed/Med-
line and Web of Science databases using the fol-
lowing keywords: “bipolar disorder and genes, or 
gene regions, or genome-wide association, or ge-
nomic mutations, or chromosome”. We applied the 
following restrictions: latest 6 years; systematic re-
view or meta-analysis; including data on humans. 
Furthermore, the references of all articles identi-
fied were carefully searched for additional studies. 
We reviewed all papers published in the English 
language from 31 December 2013 to 31 December 
31, 2019, with an update on 30 May 2020.
Inclusion Criteria
Criteria for inclusion were:
- written in English;
- being a systematic review or a meta-analysis;
- should include studies with potential risk 
genes associated with bipolar disorder.
Scoping reviews and narrative reviews that 
were not systematic were excluded. Indeed, all 
studies that did not meet inclusion criteria were 
excluded. Supplementary Table A includes the 
titles of the excluded articles.
Data Extraction and Analysis
Two authors inspected the list of the retrieved 
articles. An evaluator inspected the title and ab-
stract of the retrieved articles to establish whether 
they were congruent with the search criteria. A 
second, more experienced reviewer crosschecked 
this inspection. Duplicates were eliminated. Dis-
crepancies were solved by discussion. Articles 
that passed the first check were thoroughly read 
to confirm they met the inclusion criteria. Again, 
a senior evaluator crosschecked again the first 
check by the junior evaluator. Collected articles 
were then thoroughly reexamined for content to 
confirm that they were congruent with the in-
clusion criteria, and their references section was 
scanned to identify missed systematic reviews or 
meta-analyses. The same procedure was applied 
to the scanning of the additional sources (Figure 
1). The following data were extracted from the ar-
ticle: the name of the study, name of the author, 
publisher and year, in which country the system-
atic review/meta-analysis was done, which genes 
are analyzed, investigated genes mutations, how 
many studies are included, which databases are 
used, and what are the conclusions and recom-
mendations.
Included Papers and Qualitative 
Assessment
We found 57 unduplicated studies (systemat-
ic review and meta-analysis). After this initial 
literature search, 19 meet criteria for inclusion 
and were selected for this systematic review. 
Table I sums up the details of the precise de-
scription and main findings of the included 
systematic reviews and meta-analysis. The 
critical qualitative appraisal of the systematic 
reviews and meta-analyses was done with the 
Scottish Intercollegiate Guidelines Network 
(SIGN) implementation of the assessment of 
multiple systematic reviews (AMSTAR)9. The 
SIGN implementation of the AMSTAR is rich 
in clarifications and notes to apply the scores10. 
Two evaluators independently assigned the rate 
to each item of the SIGN’s AMSTAR. Rating 
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“yes” was assigned when the criterion was 
present. When the criterion was not met or it 
was uncertain whether it was met or not, the as-
signed rating was “no”. A global score of “high 
quality”, “acceptable quality”, and “low quali-
ty” was assigned based on this detailed evalua-
tion. Supplementary Table B summarizes the 
full evaluation of the included articles.
Data Synthesis and Presentation
We tabulated the main characteristics of the 
retrieved systematic reviews and meta-analyses. 
We also summarized the main findings with a fo-
cus on the outcome of interest. The qualitative as-
sessment of the retrieved systematic reviews and 
meta-analyses was tabulated and discussed with 
reference to the main findings of each review.  
Results
Out of 57 records that were identified after du-
plicates were removed, we identified 19 systemat-
ic reviews/meta-analyses that covered the investi-
gated topic (Table I). 
Figure 1. Prisma Flow Diagram.
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The Most Significant Susceptibility 
Genetic Factors Associated with BD
The most commonly associated genes to bipo-
lar disorder up to date are: CACNA1C, ANK3, 
NCAN, BDNF, COMT, 5-HTTLPR, NRG1, and 
FADS1. CACNA1C (calcium voltage-gated chan-
nel subunit alpha1 c) gene is generally considered 
the cardinal one for BD so far according to the 
latest genome-wide association studies (GWAS)11. 
It is known that encodes the L-type voltage-de-
pendent calcium channel 1C subunit. As claimed 
by two GWAS, its SNP rs1006737 is suggested as 
a risk variant for bipolar disorder12. An interesting 
fact is that the BD carriers of this risk genetic vari-
ant have a reduced volume of the left putamen13 
and increased activity of the amygdala in facial 
affect recognition task14. Modification of its ex-
pression has been observed in the frontal cortex 
in BD cases15. Next, the ANK3 (ankyrin 3) gene 
encodes a protein responsible for the stabilization 
and proper localization of ion channels, as well 
as for cell adhesion to Ranvier’s nodes and initial 
axon segments16. Different genetic alleles from 
it may affect the white matter structure of the 
brain. A link between bipolar disorder and SNP 
rs10994336 has been shown. This genetic variant 
is involved in cognitive function, especially im-
portant in brain deficiency17. On the other hand, 
the risk C-allele of rs10761482 SNP is associated 
with impaired verbal expression, impaired speed 
of processing the information in the brain, and 
impaired logical memory. In patients with BD, 
more precisely in carriers of this genetic allele are 
found reduce in fractional anisotropy (FA) in the 
forceps minor18. A very important thing to note 
is that this gene potentially plays a major role in 
myelination in BD19. To sum up, different genetic 
alleles of the ANK3 gene mainly affect the white 
matter of the brain, which might lead to cognitive 
decline.
Besides, genetic risk factor SNP (rs1064395) in 
the NCAN (neurocan) gene has the potential to be 
a risk factor for bipolar disorder only in Europe-
ans and Africans20. It is thought to play a function 
in structural changes in the cerebral cortex in in-
dividuals with BD21. This gene encodes a protein 
that balances cell adhesion, cell migration, and 
axon direction. The BNDF protein, which is en-
coded by the BNDF (brain-derived neurotropic 
factor) gene on chromosome 11p14.1, as a member 
of the superfamily of neurotrophins, participates 
in the differentiation of neurons, neuronal contin-
uance, and the dependent plasticity of synapses in 
developed neurons22. The SNP rs6265 of it leads to 
a change in the nucleotide 196 (G/A), resulting in 
Val66Met substitution23. There is evidence24 that 
patients with bipolar disorder and carriers of this 
risky allele have decreased hippocampal volume. 
This risk gene allele is also associated with an in-
creased predisposition to suicide in BD25. On the 
other hand, there are also studies that show that 
there is no link between this risky genetic allele 
and bipolar disorder26. Many authors27 think that 
BDNF gene has a central place in the pathophysi-
ology of bipolar disorder. A recent meta-analysis28 
shows that the peripheral level of the protein en-
coded by this gene can be used as a potential bio-
marker to assess the activity of bipolar disorder. 
According to these authors28, hypermethylation of 
the BDNF exon 1 promoter has also been report-
ed in BD. COMT (catechol-o-methyltransferase) 
gene catalyzes the transfer of the methyl group 
to catecholamines, such as the neurotransmit-
ters epinephrine, norepinephrine and dopamine. 
COMT 158Val allele has been linked to increased 
levels of schizotypy in patients with bipolar disor-
der who suffered trauma in childhood29. Further-
more, COMT 158Val/Val genotype is the main 
predictor of lower global cognitive presence in 
patients with bipolar disorder30. As far as for the 
5-HTTLPR (serotonin-transporter-linked poly-
morphic region) gene, one study31 found that the 
S allele of this gene might be affected by early 
life stress on the gray matter of the brain in the 
right prefrontal cortex in patients with BD. More-
over, this allele also was associated with an ele-
vated volume of the right amygdala in the same 
group of patients32. The NRG (neuregulin 1) gene 
participates in the formation of myelin, synaptic 
transmission, and the survival of neurons and gli-
al cells33. 
In patients with bipolar disorder, carriers of 
the NRG SNP (SNP8NRG221533) are associat-
ed with increased white matter mass in the cin-
gulum, para-hippocampal gyrus, and the corpus 
callosum compared with non-carriers34. Table II 
includes the names, functions, and relations of the 
potential genes associated with bipolar disorder, 
according to the findings from included studies.
The Implication of the ZNF804A 
Gene in BD
The ZNF804A (zinc finger protein 804A) 
gene has been often related to bipolar disorder. 
ZNF804A gene is predominantly expressed in 
the brain. After birth, ZNF804A appearance 
is decreased suggesting that it probably per-
forms a critical function in brain reorganization, 
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Gene Name Function / Relation with Bipolar disorder
ZNF804A Zinc Finger Protein 804A Polymorphisms in this gene are thought to confer an increased 
predisposition to schizophrenia, bipolar disorder, and heroin 
addiction86. The rs1344706 SNP at chromosome 2q32.1 of ZN-
F804A is the first risk factor for bipolar disorder and was recog-
nized by GWAS42.
ANK3 Ankyrin 3 Ankyrins are a family of proteins that are believed to link the in-
tegral membrane proteins to the underlying spectrin-actin cyto-
skeleton. They play key roles in activities such as cell motility, 
activation, proliferation86. The C allele in rs10994415 of ANK3 is 
associated with bipolar disorder77.
CAC
NA1C
Calcium Voltage-Gated Channel Subunit 
Alpha1 C
Encodes an alpha-1 subunit of a voltage-dependent calcium chan-
nel86. Rs1006737 and rs2159100 are the most studied SNP varia-
tions from this gene for in mood disorders, including and bipolar 
disorder68.
TENM4 Teneurin Transmembrane Protein 4 The protein encoded by this gene plays a role in establishing prop-
er neuronal connectivity during development86. The hot-spot mu-
tations reported in this gene in patients with bipolar disorder are 
the variants rs12576775 and rs1713817168.
POU3F2 POU Class 3 Homeobox 2 POU3F2 is a protein-coding gene. The POU3F2 protein is associ-
ates with bipolar disorder. It is involved in the neocortex develop-
ment in mice and is linked to a single nucleotide polymorphism, 
Rs1906252, that is associated with a cognitive phenotype: speed 
of processing information in the brain68.
ERBB2 Erb-B2 Receptor Tyrosine Kinase 2 Encodes a member of the epidermal growth factor (EGF) receptor 
family of receptor tyrosine kinases86. The importance of ERBB2 
in bipolar disorder is further supported by a genome-wide signif-
icant association finding and by the observation of dysregulated 
ERBB2 expression in the dorsolateral prefrontal cortex70. 
TRANK1 Tetratricopeptide Repeat and Ankyrin Re-
peat Containing 1
Protein coding gene. Diseases associated with TRANK1 include epi-
leptic encephalopathy and bipolar disorder. The main studied SNP is 
rs9834970 which is about 12 kb at 3 ‘UTR of the TRANK1 gene68.
FADS1 Fatty Acid Desaturase 1 Highly associated with the plasma levels of n-3/n-6 polyunsaturat-
ed fatty acids and other general lipids (i.e., HDL/LDL/TG/T-cho-
lesterol). The susceptibility SNP for bipolar disorder is the quanti-
tative trait loci SNP with such blood lipid traits121.
MTHFR Methylenetetrahydrofolate Reductase The encoded MTHFR enzyme catalyzes the conversion of 5, 
10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a 
co-substrate for homocysteine remethylation to methionine86. The 




Calcium Voltage-Gated Channel Subunit 
Alpha1 D 
Mediates the entry of calcium ions into cells. Rare variants in the 
calcium channel genes (CACNA1B, CACNA1C, CACNA1D) are 
connected with bipolar disorder and may influence treatment re-
sponse to lithium40. 
CACNB2 Calcium Voltage-Gated Channel Auxiliary 
Subunit Beta 2
CACNB2 gene polymorphisms were involved in mood disorders 
and bipolar disorder123. 
GNAS BRCA2 DNA Repair Associated Control the activity of endocrine glands through adenylate cyclase 
enzyme86. SNPs in the GNAS gene were associated with bipolar 
disorder (rs6064714, rs6026565, rs35113254)124.
TCF7L2 Transcription Factor 7 Like 2 Regulate blood glucose and homeostasis86. Genome-wide associ-
ation study of bipolar disorder in European Americans recognizes 
a new risk allele (rs12772424-A/T) within the TCF7L2 gene125. 
HTR1A 5-Hydroxytryptamine Receptor 1A Encodes a G protein-coupled receptor for 5-hydroxytryptamine 
(serotonin) and belongs to the 5-hydroxytryptamine receptor sub-
family86. A remarkable decline in HTR1A mRNA levels in the brain 
of patients with mood disorders and bipolar disorder was found126.
Table II. Potential risk genes for bipolar disorder.
Table continued
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Gene Name Function / Relation with Bipolar disorder
CRY1 Cryptochrome Circadian Regulator 1 It regulates the circadian clock. Polymorphisms in CRY1 gene 
were notably related to bipolar disorder127.
IGF1 Insulin Like Growth Factor 1 The protein encoded by this gene is similar to insulin in function 
and structure. An overexpression of IGF1 gene of bipolar disorder 
patients who react well for lithium treatment was also described76.
ITIH1 Inter-Alpha-Trypsin Inhibitor Heavy Chain 1 Encodes a member of the inter-alpha-trypsin inhibitor family 
of proteins. Among its related pathways are cell adhesion and 
cell-matrix glycoconjugates86.
ITIH3 Inter-Alpha-Trypsin Inhibitor Heavy Chain 3 Encodes the heavy chain subunit of the pre-alpha-trypsin inhibitor 
complex86. 
ITIH4 Inter-Alpha-Trypsin Inhibitor Heavy Chain 4 Genetic variants located in the regions of ITIH1, ITIH3, ITIH4 
genes were associated with bipolar disorder and suicidal attempt 
in bipolar disorder patients128. 
BDNF Brain Derived Neurotrophic Factor Encodes a member of the nerve growth factor family of proteins. 
Expression of this gene is reduced in Alzheimer’s, Parkinson’s, 
and Huntington’s disease patients86. The Val66Met polymorphism 
was connected with depressive disorder, bipolar disorder and also 
suicidal behavior in depressed and bipolar disorder patients129.
CREB1 CAMP Responsive Element Binding Pro-
tein 1
Involved in different cellular processes including thesynchroni-
zation of circadian rhythmicity and the differentiation of adipose 
cells86. The CREB1 gene variants (rs6785, rs2709370) were asso-
ciated with increased bipolar disorder vulnerability. Other SNPs 
on the CREB gene were proposed for bipolar disorder and lithium 
response75.
NCAN Neurocan Modulation of cell adhesion and migration86. SNP (rs1064395) in 
NCAN gene was established to be a risk factor for bipolar disor-
der in the European population20.
GSK3B Glycogen Synthase Kinase 3 Beta The protein encoded by this gene is a serine-threonine kinase be-
longing to the glycogen synthase kinase subfamily. Diseases as-
sociated with GSK3B include Alzheimer’s Disease and Bipolar 
Disorder86. In addition, rare variants in the GSK3B gene showed 
the risen risk for bipolar disorder130.
SLC18A1 Solute Carrier Family 18 Member A1 The vesicular monoamine transporter which accumulates cy-
tosolic monoamines into vesicles, using the proton gradient 
maintained across the vesicular membrane86. Variations in the 
SLC18A1 (rs988713, rs2279709, Thr136Ser) gene show suscepti-
bility to bipolar disorder131.
COMT Catechol-O-Methyltransferase Catalyzes the transfer of a methyl group from S-adenosylmethi-
onine to catecholamines, including the neurotransmitters dopa-
mine, epinephrine, and norepinephrine86. COMT 158Val/Val gen-
otype is a bold predictor of lower global cognitive presentation in 
patients with bipolar disorder30.
FKBP5 FKBP Prolyl Isomerase 5 The protein encoded by this gene is a member of the immunophi-
lin protein family, which play a role in immunoregulation and ba-
sic cellular processes involving protein folding and trafficking86. 
FKBP5 does play a role in the predisposition for bipolar disorder 
as well as in repetition of depression and rapidity of response to 
antidepressant medication62.
S100B S100 Calcium Binding Protein B S100B proteins are localized in the cytoplasm and/or nucleus of 
a broad range of cells involved in the regulation of a number of 
cellular processes such as cell cycle progression and differentia-
tion86. SNPs as an example rs2339350 and rs3788266 are strongly 
associated with bipolar disorder132.
YWHAH Tyrosin 3-Monooxygenase/Tryptophan 
5-Monooxygenase Activation Protein Eta
This gene product belongs to the 14-3-3 family of proteins which me-
diate signal transduction by binding to phosphoserine-containing pro-
teins86. One SNP (rs2246704) is actively related to bipolar disorder133.
Table II. (Continued). Potential risk genes for bipolar disorder.
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Gene Name Function / Relation with Bipolar disorder
NRG1 Neuregulin 1 The protein encoded by this gene is a membrane glycoprotein that 
mediates cell-cell signaling and plays a critical role in the growth 
and development of multiple organ systems86. Bipolar disorder 
was also noticed to be positively related to two polymorphisms 
(d2s436 and d13s785) of two loci (2p11q14 and 13q21-33,) in a 
family-based study. NRG1 plays a role in the pathophysiology of 
bipolar disorder and could be considered as a biomarker of the 
disorder134.
DAOA D-Amino Acid Oxidase Activator This gene encodes a protein that may function as an activator of 
D-amino acid oxidase, which degrades the gliotransmitter D-ser-
ine, a potent activator of N-methyl-D-aspartate (NMDA) type glu-
tamate receptors86. SNP (rs1935062) in this gene is significantly 
associated with bipolar disorder135. 
WFS1 Wolframin ER Transmembrane Glycopro-
tein
This gene encodes a transmembrane protein, which is located pri-
marily in the endoplasmic reticulum and ubiquitously expressed 
with highest levels in the brain, pancreas, heart, and insulinoma 
beta-cell lines86. Several studies have directly involved WFS in the 
etiopathogenesis of bipolar disorder136. 
DUSP6 Dual specificity
phosphatase 6
This gene is known to negatively regulate member of the MAP 
kinase superfamily, which play a role in neuronal differentiation, 
neuronal survival, and long term neuroplasticity137. Some studies 
suggest an association between DUSP6 and bipolar disorder138.
NPY Neuropeptide Y This gene encodes a neuropeptide that is widely expressed in the 
central nervous system and influences many physiological pro-
cesses, including cortical excitability, stress response, food intake, 
circadian rhythms, and cardiovascular function. It was found that 
NPY mRNA expression is remarkable declined in the prefrontal 
cortex of subjects affected by bipolar disorder116.
GRIK2 Glutamate receptor ionotropic
kainate 2 isoform precursor
Glutamate receptors are the predominant excitatory neurotrans-
mitter receptors in the mammalian brain and are activated in a 
variety of normal neurophysiologic processes86. GRIK2 gene 
probably plays a role in suicidal ideation in patients with bipolar 
disorder139.
SLC6A4 Solute Carrier Family 6 Member 4 This gene encodes an integral membrane protein that transports 
the neurotransmitter serotonin from synaptic spaces into presyn-
aptic neurons86. Differential methylation of serotonin 2A receptor 
(SLC6A4) in patients with bipolar disorder is found140.
GDNF Glial Cell Derived Neurotrophic Factor Encodes a secreted ligand of the TGF-beta (transforming growth 
factor-beta) superfamily of proteins86. This gene also being indi-
cated in studies with bipolar patients141.
SYN2 Synapsin II This gene is a member of the synapsin gene family. Synapsins 
encode neuronal phosphoproteins which associate with the cyto-
plasmic surface of synaptic vesicles86. Synapsin II is involved in 
the modulation of neurotransmitter release in patients with bipolar 
disorder142.
PDLIM5 PDZ And LIM Domain 5 It is thought to function in cardiomyocyte expansion and in re-
straining postsynaptic growth of excitatory synapses86. There was, 
however, a major difference in the expression of PDLIM5 mRNA 
in BD patients compared to controls, which may show that it is a 
good marker for BD in general143.
MT-ND1 Mitochondrially Encoded NADH:Ubiqui-
none Oxidoreductase Core Subunit 1
In patients diagnosed with bipolar disorder, it was also found ele-
vated levels of mutated mtDNA copies144. In patients with bipolar 
disorder, one of the variants was found in MT-ND1 protein coding 
gene145.
MT-CYB Mitochondrially Encoded Cytochrome B In patients diagnosed with bipolar disorder, it was also found ele-
vated levels of mutated mtDNA copies144. In patients with bipolar 
disorder one of the variants was found in MT-CYB protein-coding 
gene145.
Table II. (Continued). Potential risk genes for bipolar disorder.
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Gene Name Function / Relation with Bipolar disorder
HSPF1 
(DNAJB1)
DnaJ Heat Shock Protein Family (Hsp40) 
Member B1
Encodes a member of the DnaJ or Hsp40 (heat shock protein 40 
kD) family of proteins86. The gene HSPF1 has been found to be 
up-regulated in post-mortem brain from patients diagnosed with 
bipolar disorder146.
NR1D1 Nuclear Receptor Subfamily 1 Group D 
Member 1
Encodes a transcription factor that is a member of the nuclear re-
ceptor subfamily 186. When the circadian clock genes were exam-
ined with respect to lithium response in bipolar disorder, using 
LCLs, it was shown that lithium response was best seen by the A 
allele of NR1D1 rs207142774.
RASGRP1 RAS Guanyl Releasing Protein 1 This gene is a member of a family of genes characterized by the 
presence of a Ras superfamily guanine nucleotide exchange factor 
(GEF) domain86. A very important finding was down-regulation of 
RASGRP1. RASGRP1 codes for a guanyl nucleotide exchange 
factor that activates ras, and has binding domains for Ca2+ and 
diacylglycerol147.
POLG1 DNA Polymerase Gamma, Catalytic Subu-
nit
The major finding was down-regulation of POLG1 gene in pa-
tients with bipolar disorder. POLG1 gene codes for the catalytic 





In patients with bipolar disorder, it is found that carriers of the 
5-HTTLPR S (i.e., short) allele had increased radial diffusivity in 
several brain white matter tracts, including the cingulum gyrus, 
corpus callosum (body and genum) and corona radiata compared 
to non-carriers72.
SREBF2 Sterol Regulatory Element Binding Tran-
scription Factor 2 
This gene encodes a member of the ubiquitously expressed tran-
scription factor that controls cholesterol homeostasis. In the pa-
tients with bipolar disorder, it is found that SREBF2 rs1052717 
polymorphism A/A genotype leads to increased radial diffusivity 
and reduced FA (fractional anisotropy) in the cingulum, corpus 
callosum, superior and inferior longitudinal fasciculi, and anterior 
thalamic radiation71.
TPH2 Tryptophan hydroxylase 2 This gene encodes a member of the pterin-dependent aromatic 
acid hydroxylase family. The encoded protein catalyzes the first 
and rate limiting step in the biosynthesis of serotonin, an import-
ant hormone and neurotransmitter86. Elevated levels of TPH2 ex-
pression have been found in the dorsolateral prefrontal cortex of 
patients with bipolar disorder148.
TPH1 Tryptophan Hydroxylase 1 This gene encodes a member of the aromatic amino acid hydrox-
ylase family. The encoded protein catalyzes the first and rate-lim-
iting step in the biosynthesis of serotonin, an important hormone, 
and neurotransmitter86. Three polymorphisms of TPH1(A218C, 
A779C, and A6526G) have been examined, and some studies 
showed a remarkable relation of this gene with the risk of suicide 
in the patients of bipolar disorder46.
AKT1 AKT Serine/Threonine Kinase 1 The serine-threonine protein kinase encoded by the AKT1 gene is 
catalytically inactive in serum-starved primary and immortalized 
fibroblasts86. This gene is associated with the risk of suicide and 
violent attack attempts in patients with bipolar disorder49.
ADRA2 Adrenoceptor Alpha 2A Alpha-2-adrenergic receptors are members of the G protein-cou-
pled receptor superfamily. The alpha-2-adrenergic receptors are a 
type of adrenergic receptors (for adrenaline or epinephrine), which 
inhibit adenylate cyclase86. Some variants of this gene (including 
the promoter N521K, C1291G, rs11195419) have been associated 
with suicide in patients with bipolar disorder52.
Table II. (Continued). Potential risk genes for bipolar disorder.
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which might lead to BD35. Promising risk genetic 
variants of it is rs1344706 were assumed to be in-
volved in suicide-attempt efforts in BD patients36. 
The rs1344706 SNP at chromosome 2q32.1 of the 
ZNF804A gene is the first risk factor for bipolar 
disorder identified by GWAS. Different stud-
ies37 from different European populations show 
that rs1344706 is likely a risk SNP for bipolar dis-
order in Europeans.
BD and Genes Involved in Calcium 
Signaling
The effect of calcium signaling in bipo-
lar disorder has been studied for a long time. 
Certain genetic findings have shown38 that im-
paired calcium signaling is probably responsible 
for the pathophysiology of bipolar disorder. It has 
been found39 that there are modifications in calci-
um levels in the cerebrospinal fluid observed in 
mania. One of the biggest culprits for impaired 
calcium signaling mediated by LTCCs (L-type 
calcium channels) is the abovementioned CAC-
NA1C gene which encodes the LTCC Cav1.2 α1 
subunit. Other genes included in this group are 
CACNA1D gene (calcium voltage-gated channel 
subunit alpha1 d) which encodes the Cav1.3 α1 
subunit and CACNB2 gene (calcium voltage-gat-
ed channel auxiliary subunit beta 2), which en-
codes the β2 subunit40. The importance of LTCCs 
is reflected in the fact that they are involved in 
memory and circadian rhythm, which are of par-
ticular importance for BD. Hence, they are signif-
icant because of their use as a target for antago-
nists in the treatment of BD41.
DNA Methylation in BD
DNA methylation of peripheral tissues is an-
other phenomenon observed in bipolar disorder. 
Receptors, neurotransmitters, and transporters 
are most commonly methylated. In two studies, 
hypermethylation of the exon 1 promoter of the 
BNDF was observed42,43. As mentioned above, 
BDNF is a neurotrophin, and its levels in the pe-
ripheral blood are reduced in BD cases44. More-
over, hypermethylation of 5-HTR1A (hydroxy-
tryptamine serotonin 1A receptor) gene has been 
reported in patients with BD45.
BD and Risk Suicide Genes
Completed suicide is a crucial cause of death in 
patients with bipolar disorder. In the latest years 
several studies focused on the potential candidate 
genes associated with suicidal behavior in bipo-
lar disorder. Candidate gene-based association 
Table II. (Continued). Potential risk genes for bipolar disorder.
Gene Name Function / Relation with Bipolar disorder
DRD2 Dopamine Receptor D2 Encodes the D2 subtype of the dopamine receptor. This G-protein 
coupled receptor inhibits adenylyl cyclase activity86. DRD2 is in-
volved in the etiology and it is probably a general risk factor for 
bipolar disorder149.
HTR2C 5-Hydroxytryptamine Receptor 2C Encodes a seven-transmembrane G-protein-coupled receptor. The 
encoded protein responds to signaling through the neurotransmit-
ter serotonin86. There is an association between early-onset bipolar 
disorder and Cys23Ser polymorphism of this gene150.
TLR4 Toll Like Receptor 4 The protein encoded by this gene is a member of the Toll-like re-
ceptor (TLR) family which plays a fundamental role in pathogen 
recognition and activation of innate immunity86. Two SNPs in the 
TLR4 gene are associated with bipolar disorder and early-onset 
bipolar disorder (rs1927914 and rs11536891)60.
TLR2 Toll Like Receptor 2 The protein encoded by this gene is a member of the Toll-like re-
ceptor (TLR) family which plays a fundamental role in pathogen 
recognition and activation of innate immunity86. Two SNPs in the 
TLR2 are related to early-onset bipolar disorder (rs3804099 TT 
and TLR2 rs4696480)59.
TSPO Translocator Protein The protein encoded by this gene is a key factor in the flow of 
cholesterol into mitochondria to permit the initiation of steroid 
hormone synthesis86. It was found an association between bipolar 
disorder and the rs6971 polymorphism in the TSPO gene, which 
is possible to modify the process of synthesis of steroids or its 
regulation151.
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studies have given important evidence about 
the integration of genetic variation in suicidal 
presence. According to certain studies46,47, poly-
morphisms from the TPH1 (tryptophan hydrox-
ylase 1)46 and TPH2 (tryptophan hydroxylase 2)47 
genes have been shown to be a risk factor for in-
creased suicide attempts. This group also includes 
the gene responsible for transporting the serotonin, 
SLC6A4 (solute carrier family 6 member 4) gene, 
which is also the central gene for suicide-related 
research in BD cases48. Intriguingly, according to 
one study, an association was found between the 
AKT1 (AKT serine/threonine kinase 1) gene and 
suicide attempts and attempts with violence in 
BD49. As reported by another study50, a link was 
found between the GSK3B (glycogen synthase 
kinase 3 beta) gene and an increased level of im-
pulsivity, and thus an increased risk of suicide in 
BD individuals. The well-known BDNF gene is 
also known to be bound to suicide. A post-mor-
tem study identified decreased levels of BDNF 
mRNA in the hippocampus and prefrontal cor-
tex of suicide BD subjects51. In addition, ADRA2 
(adrenoceptor alpha 2A)52 and COMT53 have been 
identified as potential risk suicide genes. Further 
research is definitely required, and other genes 
have to be taken into consideration. Other poten-
tial genes can be found listed in Table II.
Susceptibility Genes for Early-Onset BD
A specific feature of bipolar disorder is that 
early-onset has a significantly less favorable prog-
nosis than late-onset. Therefore, it is important to 
identify potential genes associated with the etiol-
ogy of early onset of bipolar disorder. There are 
several genes that have a potential impact on the 
onset of BD at an early age. One of those genes 
is the aforementioned BDNF gene. The BDNF 
Val allele was found more prevalent in patients 
with early-onset bipolar disorder than in those 
with late-onset BD54. Also, the DRD2 (dopamine 
receptor d2) gene has a significant association 
with the onset of BD at an early age55; however, 
some studies didn’t find an association56. The role 
of COMT as a risk gene has been also evaluated. 
Several studies57,58 have found an association be-
tween Val/Met SNP and early-onset BD. In recent 
years, the importance of the TLR2 (toll-like re-
ceptor 2)59 and TLR4 (toll-like receptor 4)60 genes 
as potential genes responsible for the pathogene-
sis of early BD has been emphasized. Two SNPs 
(rs3804099 TT and rs4696480 TT) from TLR259 
and two SNPs from TLR460 (rs1927914 and 
rs11536891) are found as a strongly associated. 
Meanwhile, GWAS found that a small number of 
polymorphisms in the CACNA1C gene, as well as 
genes that encode proteins on the cell surface or 
make up the extracellular matrix, such as TENM4 
(teneurin transmembrane protein 4), ANK3, and 
NCAN, can be considered genes involved in ear-
ly-onset BD61.
Candidate Genes for Both BD and 
Schizophrenia
Several studies pointed out that there is a 
genetic overlap between bipolar disorder and 
schizophrenia. One of the genes is the FKBP5 
gene. Its carriers have a predisposition for devel-
oping bipolar disorder62. In the postmortem study 
of patients with schizophrenia, increased levels of 
FKBP5 (FKBP prolyl isomerase 5) gene mRNA 
were found63. Another interesting gene that is also 
linked to both psychiatric illnesses is MTHFR 
(methylenetetrahydrofolate reductase) gene. This 
gene is important for folate metabolism because 
it is involved in obtaining 5-MTHF or circulating 
folate form64. C677T polymorphism of this gene 
is expected as a risk for developing both BD and 
schizophrenia. However, this polymorphism has 
an impact on the age at onset of BD but not the age 
at onset of schizophrenia65. Other susceptibility 
genes in this group are ZNF804A66, COMT67, and 
BDNF67. Further research is definitely required, 
and other genes have to be taken into consider-
ation. Other potential genes can be found listed 
in Table II.
Cognitive Status in BD Cases
The decline in cognitive status in patients with 
bipolar disorder is of great significance. Specific 
genes are thought to play a major role in this pro-
cess. POU3F2 (POU class 3 homeobox 2) is con-
sidered to be one of the most essential risk genes 
for the cognitive status in BD patients. SNP from 
this gene (rs1906252) is associated with the speed 
of processing the information in the brain68. As 
already mentioned, COMT 158Val/Val genotype 
is the main predictor of lower global cognitive 
presence in patients with BD30.
Structural Alteration in BD Brain Tissue 
Structural changes in brain tissue are widely 
observed in BD. Some genes are thought to play 
a vital part in their formation. TPH2 gene is one 
of the most mentioned genes in this category. The 
protein encoded by this gene plays a role in cata-
lyzing serotonin biosynthesis. Increased levels of 
expression of this gene in the dorsolateral prefron-
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tal cortex have been reported in patients with BD69. 
Moreover, the expression of dysregulated ERBB2 
(erb-b2 receptor tyrosine kinase 2) gene in the pre-
frontal dorsolateral cortex was found in patients 
with BD70. The SNP (rs1052717) of SREBF2 (ste-
rol regulatory element binding transcription factor 
2) gene responsible for homeostasis of cholesterol 
probably gives rise to increased radial diffusivity 
and reduced FA in the cingulum, corpus callosum, 
superior and inferior longitudinal fasciculi, and an-
terior thalamic radiation71. In patients with bipolar 
disorder, it is noticed that carriers of the 5-HTTL-
PR S (i.e., short) allele have growth of radial dif-
fusivity in numerous brain white matter tracts, in-
cluding the corpus callosum, cingulum gyrus, and 
corona radiate in comparison to non-carriers72. It 
is also shown that the mRNA expression of NPY 
(neuropeptide y) gene is remarkably declined in 
the prefrontal cortex of subjects affected by bipolar 
disorder73. 
Lithium Response and Genes in BD
Lithium (anti-manic agent) is one of the most 
frequently used and studied medications for treat-
ing bipolar disorder. Good responders of thera-
py with lithium usually have a family history of 
disorders, such as bipolar disorder, melancholic 
depression, and euphoric mania. This suggests 
that lithium-responsive BD cases might be a ge-
netically visible phenotype74. When the circadian 
clock genes were examined with respect to lithi-
um response in bipolar disorder, using LTCCs, it 
was shown that lithium response was best seen by 
the A allele of NR1D1 (nuclear receptor subfami-
ly 1 group d member 1) gene (rs2071427)74. Also, 
SNPs on the CREB1 (CAMP responsive element 
binding protein 1) gene were proposed as respon-
sible for bipolar disorder and lithium response75. 
Moreover, it was described an overexpression 
of the IGF1 (insulin like growth factor 1) gene 
in patients with bipolar disorder who react well 
for lithium treatment76. Because of these studies, 
the phenotype of people with BD who are good 
responders to lithium can be used to map their 
genetic risk. On the other side of the coin, FKBP5 
gene is a susceptibility gene for the rapidity of re-
sponse to antidepressant medication in BD77.
Discussion
This systematic review highlights findings of 
the genetic background of bipolar disorder show-
ing evidence of potential and promising risk genes 
that are linked with multiple facets of bipolar dis-
order, from a total of 19 reviewed studies (sys-
tematic reviews and meta-analysis). In the last 20 
years, special attention has been paid to the genet-
ic factors involved in various ways in the complex 
spectrum of BD. It is increasingly acknowledged 
that BD has a genetic basis with a heritability of 
up to 80%78. The sex of the transmitting parent 
seems to play a decisive role in the transmission 
of BD79. We divided our findings in: 1) a list of 
the most significant susceptibility genetic factors 
associated with BD; 2) the implication of the ZN-
F804A gene in BD; 3) the role of genes involved in 
calcium signaling in BD; 4) DNA methylation in 
BD; 5) BD and risk suicide genes; 6) susceptibil-
ity genes for early-onset BD; 7) candidate genes 
common to both BD and schizophrenia; 8) genes 
involved in cognitive status in BD cases; 9) genes 
involved in structural alteration in BD brain tis-
sue; 10) genes involved in lithium response in BD.
The comprehensive number of risk alleles, their 
prevalence, and their effect proportion point to the 
genetic architecture of a certain phenotype or fea-
ture. However, although remarkable heritability 
indicates that genetics plays a key role in disease, 
the authentic genetic architecture underlying the 
heritability cannot be estimated and needs to be 
settled empirically. According to our evidence, 
the genes most commonly associated with bipo-
lar disorder up to date are CACNA1C, ANK3, 
NCAN, BDNF, COMT, 5-HTTLPR, NRG1, and 
FADS1 genes.
Certain genes are known to be involved in the 
pathways of neurotransmission and neuroplastici-
ty80. This group of genes includes BDNF, which 
is known to regulate synaptic function81. The 
ZNF804A gene might be involved in disorders 
of the dopaminergic system and neurotransmis-
sion, which in turn might lead to modifications 
in dopamine concentrations in the brain. Indeed, 
the main effect of this gene in BD is through the 
regulation of genes involved in dopaminergic 
pathways82. HTR2A83 and COMT84 are known as 
lead factors implicated in the neurotransmission 
metabolism. The CREB1 (cyclic AMP-responsive 
element-binding protein 1) gene might be also 
involved in neuronal activity and binding and in 
synaptic plasticity85,86.
The CACNA1C gene appears to be the main 
carrier of modified calcium dynamic in BD, in-
termediated by LTCCs37. This evidence has been 
recently complemented by the presence of al-
tered calcium channel expression and signaling 
in patients with BD. It is affected mainly by its 
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expression in the frontal cortex15. Although the 
mechanism is not yet known, it is considered 
that CACNA1C risk single nucleotide polymor-
phisms are associated with increased expression 
and action of LTCCs. In other words, activated 
neurons from subjects-carriers of the risk CAC-
NA1C single nucleotide polymorphism demon-
strate increased expression of calcium channel 
subunit mRNA, and expanded calcium signaling, 
contrasted with those who are not carriers of risk 
gene alleles87,88. 
Nevertheless, epigenetic genome alterations at-
tribute to changes in the physical structure of the 
chromatin, without modification in the DNA con-
struction89. The most widely studied epigenetic 
modification is DNA methylation, characterized 
by the covalent linking of a methyl (CH3) group 
to a cytosine residue90. Frequent locations of epi-
genetic modifications are in areas known to di-
rect the accessibility of neurotrophins, dopamine, 
and serotonin. For instance, the BDNF gene is 
a neurotrophin whose peripheral blood levels in 
BD are reduced91. In fact, the use of peripheral 
tissue samples (blood or saliva) as research ma-
terial for BD methylation models has increased91. 
Hypermethylation of the 5-HTR1A gene is also 
described in BD cases45.
Above all, BD patients are exposed to a high 
risk of a suicide death. Identifying risk factors, 
including genetic ones, is imperative to intervene 
before it is too late. It is desirable to have genetic 
markers available, which in addition to medical 
history will serve to identify patients at increased 
risk of suicide. Family history in BD patients with 
suicide in first-generation relatives is the head risk 
factor for suicide. The genes associated with do-
pamine, serotonin, and norepinephrine have been 
investigated as genetic risk factors for this BD. In 
the last few years, GWAS are beginning to draw 
clearer conclusions about the genetic basis for sui-
cide in the BD cases. In addition to the genetic 
background, other clinical factors associated with 
an increased risk of suicide in BD include a large 
number of depressive episodes, previous suicide 
attempts, substance, and drug abuse, the onset 
of the disease at an early age, and the presence 
of anxiety disorders91. Polymorphisms in TPH146 
and TPH247 gene might be associated with this 
phenomenon which is common for BD. Accord-
ing to our data, other potential risk suicide genes 
in BD are BDNF51, ADRA252, COMT53 genes. 
The full description of the association of some 
genes and the risk of suicide in BD can be found 
listed in Table II92-151. 
Until now, little is known about the genet-
ic structure differences of the early-onset and 
late-onset subtypes of BD. An increasing num-
ber of scientists are adhering to the thesis that the 
occurrence of BD at an early age is associated 
with thousands of ordinary SNPs with small ef-
fects and by a small number of rare variants with 
enormous effects40. Rare variants can be detected 
by using GWAS and using high-resolution tech-
niques, such as whole-exome or whole-genome 
sequencing. It has been tried several times to rep-
licate the previously indicated polymorphisms in 
larger populations, but as a result, now there is an 
increasing number of new genes associated with 
BD at an early age, but also certain genes whose 
previous association with BD-early onset is com-
pletely excluded. The most susceptibility genes 
associated with early-onset BD are BDNF54, 
DRD255, COMT57, and recent TLR259, TLR460, 
and CACNA1C61 genes. The need for a standard-
ized methodology for the genetic framework of 
early-onset BD is of great importance as one step 
closer to diagnostic reflections106,109,111. 
Bipolar disorder and schizophrenia have many 
features in common. Both disorders are charac-
terized by abnormalities in behavior, cognitive 
status, thoughts, and mood107. The present evi-
dence of the family impact for these two diseases 
is an indicator for the identification of genes that 
are a risk factor for their occurrence. Recent mo-
lecular genetic studies show that there is a genet-
ic overlap between these disorders. Current data 
have found a genetic overlap of the regions on the 
chromosomes 1q, 13q, 22q, 6q, 8p, and 18108. The 
most investigated shared gene between schizo-
phrenia and BD are the FKBP563, 5-MTHF64, ZN-
F804A65, COMT67 and BDNF67 genes. 
The often-observed neurocognitive disability 
in patients with BD needs to be a therapeutic goal, 
in order to improve psychological functioning and 
quality of life in patients. The reasons for the cog-
nitive decline in the patients, especially the ge-
netic origin is one of the current topics to which 
is paid special attention. Several areas of human 
functioning in BD seem affected, such as memo-
ry, attention, and verbal learning112,113. As report-
ed by some studies, the etiological heterogeneity 
of neurocognitive fluctuation involves several risk 
genes, such as POU3F2114 and COMT114. Some 
authors115 have suggested that neurocognitive 
deficits may be recognized as the underlying en-
dophenotypes of BD.                                                   
Significantly reduced cortical thickness is 
found in patients with BD, with the greatest ef-
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fects on the temporal, parietal, and frontal areas. 
It is a known fact that the genetic machinery of 
one BD individual has a leading role in their oc-
currence. Intriguing is the fact that the mRNA 
expression of the NPY gene is reduced in the pre-
frontal cortex in individuals with BD116.
The most suitable application of genetics in pa-
tients with BD may originate from the purpose 
of pharmacogenetics, which looks over how ge-
netic variation also influences the metabolism 
and success of therapeutic drugs. Genetic studies 
in the Asian population confirm the findings of 
previous studies in the Caucasian population that 
the CHL1 (cell adhesion molecule L1 like) gene, 
which is the neuronal recognition molecule, is 
associated with resistance to antidepressant treat-
ment117. This confirmation is important because it 
is an overture to the development of methods and 
ways to plan treatment with antidepressants based 
on genetic background. Other genes thought to be 
involved in this resistance are BDNF, HTR2A, 
and RORA, but these findings are in need of inde-
pendent confirmation118.                                            
Candidate gene association studies have been 
the cornerstone of the research about the lithium 
pharmacogenetic and lithium response so far. 
Although there have been a number of pre-con-
firmed associations, the response to lithium treat-
ment based on genetic factors cannot yet be pre-
dicted with certainty. As supported by our data, 
CREB175 and the IGF176 are associated with the 
lithium response in BD. The principal reason for 
this might be pure that the biological basis and 
genetic transmission of BD continue to be mainly 
uncharacterized, thus studies established upon an 
insufficient conception of the disorder might not 
be targeting the crucial genes. GWAS concludes 
that the genetic base of BD is best considered as 
an oversized assembly of frequent alleles, each 
with minor effects that collectively report for dis-
ease risk119. Other current findings recommend 
that BD is also caused by a low number of rare 
mutations characterized with very high pene-
trance, best illustrated by copy number variants 
(CNM)120.
Limitations and Strengths
The level and quality of each study included 
in this review are different. The global quality of 
each systematic review/meta-analysis included in 
our systematic review has been evaluated accord-
ing to the SIGN implementation of the AMSTAR 
(quality assessment scale). In keeping with these 
criteria, ten of the included studies were rated 
with high quality, eight with acceptable quality, 
and only one paper was rated with low quality 
(Table B). It should be noted that a large number 
of individuals who carry the potential risk genetic 
alleles are healthy people, but this does not mean 
that they will develop the disease. Moreover, the 
genetic variants associated with BD are not only 
specific to bipolar disorder, but also to a wide 
range of other diseases. Therefore, recurrent vari-
ants are not suitable to prognoses the presence or 
nonappearance of clinical disease or the possibil-
ity of developing a disease (Table II).           
Only for certain risk genes there are data about 
their impact on certain populations. The lack of 
evidence linking a particular gene to a larger pop-
ulation is a gap that needs to be filled in the fu-
ture. It is well known that the genetic profile of a 
BD patient varies between populations. 
We could not conduct on the data a meta-analy-
sis, given the different methods used by the stud-
ies. This limitation should caution us to interpret 
the present results with some reservations. More 
studies of wider coverage are needed to assess the 
predominantly impact of the genes on BD, which 
in turn can probably aid in the development of 
possible therapeutic targets and advance of the 
treatment and outcome for BD. Another limita-
tion is the complexities of genetics, particularly 
related to BD. Mutations are often found in the 
regulatory regions, not the “genes”. But even 
when mutations are already known, we know 
that bipolar disorder has individual comportment 
of mutations. It would take tens of thousands of 
patients to likely recognize correlations, which 
is not currently achievable. The main strength of 
this review is its composition since it is systemat-
ic and includes the entire scientific evidence pub-
lished so far on the main medical databases in the 
last 6 years. New content and new potential genes 
associated with BD have been described in this 
systematic review.
Conclusions
In summary, molecular genetic findings strong-
ly endorse genetic factors conferring susceptibility 
across BD continuity. Results suggest that these 
polymorphisms may act as common vulnerabil-
ity factors or as modifiers of the BD phenotype. 
Future research should concentrate on molecu-
lar mechanisms by which genetic variants play a 
major role in BD. Collected data about the identi-
fication of susceptibility genes for BD is interest-
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ing and promising, but still insufficiently clarified. 
Supplemental research is needed to replicate the 
applicable results. In general, it is our recommen-
dation that future studies should consider a panel 
of SNPs, probably covering the full length of the 
gene, to envelop as much as available all variations 
possibly changing the expression of the gene.
Conflict of Interest
The authors state they have no conflicts of interest.
Authors’ Contributions
G. Kalcev and A. Preti searched the databases and evaluat-
ed the articles. G. Kalcev has prepared the first draft, all the 
authors have contributed to the improvement of the same. 
All authors approved the final content of the paper.
Acknowledgments 
Goce Kalcev (MD) was participating in the writing of this 
paper, in the framework of the International Ph.D in Inno-
vation Sciences and Technologies at the University of Ca-
gliari, Italy.
References
 1) Akiskal HS. The bipolar spectrum: new concep-
ts in classification and diagnosis. The American 
Psychiatric Association Annual Review 1983; 2: 
271-292.
 2) Akiskal HS. Diagnosis and classification of af-
fective disorders: new insights from clinical and 
laboratory approaches. Psychiatr Dev 1983; 1: 
123-160. 
 3) Akiskal HS. The dark side of bipolarity: detecting 
bipolar depression in its pleomorphic expres-
sions. J Affect Disord 2005; 8: 107-115.
 4) Craddock N, Sklar P. Genetics of bipolar disorder. 
Lancet 2013; 381: 1654-1662.
 5) Prien RF, Potter WZ. NIMH workshop report on 
treatment of bipolar disorder. Psychopharmacol 
Bull 1990; 26: 409-427.
 6) Smoller JW, Finn CT. Family, twin, and adoption 
studies of bipolar disorder. Am J Med Genet C Se-
min Med Genet 2003; 123: 48-58.
 7) Craddock N, Jones I. Molecular genetics of bipo-
lar disorder. Br J Psychiatry 2001; 178: 128-133.
 8) Moher D, Shamseer L, Clarke M, Ghersi D, Li-
berati A, Petticrew M, Shekelle P, Stewart LA, 
PRISMA-P Group. Preferred reporting items for 
systematic review and meta-analysis protocols 
(PRISMA-P) statement. Syst Rev 2015; 4: 1.
 9) Shea BJ, Grimshaw JM, Wells GA, Boers M, An-
dersson N, Hamel C, Porter CA, Tugwell P, Moher 
D, Bouter LM. Development of AMSTAR: a mea-
surement tool to assess the methodological quali-
ty of systematic reviews. BMC Med Res Methodol 
2007; 7: 10. 
10) SIGN. Methodology checklist 1: systematic re-
views and meta-analyses. Available at https://
www.sign.ac.uk/checklists-and-notes. 2019. 
11) Cross-Disorder Group of the Psychiatric Genomi-
cs Consortium, Smoller JW, Craddock N, Kend-
ler K, Lee PH, Neale BM, Nurnberger JI, Ripke 
S, Santangelo S, Sullivan PF. Identification of risk 
loci with shared effects on five major psychiatric 
disorders: a genome-wide analysis. Lancet 2013; 
381: 1371-1379.
12) Sklar P, Smoller JW, Fan J, Ferreira MA, Perlis 
RH, Chambert K, Nimgaonkar VL, McQueen MB, 
Faraone SV, Kirby A, de Bakker PI, Ogdie MN, 
Thase ME, Sachs GS, Todd-Brown K, Gabriel 
SB, Sougnez C, Gates C, Blumenstiel B, Defelice 
M, Ardlie KG, Franklin J, Muir WJ, McGhee KA, 
MacIntyre DJ, McLean A, VanBeck M, McQuillin 
A, Bass NJ, Robinson M, Lawrence J, Anjorin A, 
Curtis D, Scolnick EM, Daly MJ, Blackwood DH, 
Gurling HM, Purcell SM. Whole-genome asso-
ciation study of bipolar disorder. Mol Psychiatry 
2008; 13: 558-569.
13) Perrier E, Pompei F, Ruberto G, Vassos E, Collier 
D, Frangou S. Initial evidence for the role of CAC-
NA1C on subcortical brain morphology in patien-
ts with bipolar disorder. Eur Psychiatry 2011; 26: 
135-137. 
14) Jogia J, Ruberto G, Lelli-Chiesa G, Vassos E, Ma-
ieru M, Tatarelli R, Girardi P, Collier D, Frangou C. 
The impact of the CACNA1C gene polymorphism 
on frontolimbic function in bipolar disorder. Mol 
Psychiatry 2011; 16: 1070-1071. 
15) Nurnberger JI-Jr, Koller DL, Jung J, Edenberg 
HJ, Foroud T, Guella I, Vawter MP, Kelsoe JR, 
Psychiatric Genomics Consortium Bipolar Group. 
Identification of pathways for bipolar disorder: a 
meta-analysis. JAMA Psychiatry 2014; 71: 657-
664.
16) Gasser A, Ho TS, Cheng X, Chang KJ, Waxman 
SG, Rasband MN, Dib-Hajj SD. An ankyrinG-bin-
ding motif is necessary and sufficient for targeting 
Nav1.6 sodium channels to axon initial segments 
and nodes of Ranvier. J Neurosci 2012; 32: 7232-
7243.
17) Dima D, Jogia J, Collier D, Vassos E, Burdick KE, 
Frangou S. Independent modulation of engage-
ment and connectivity of the facial network during 
affect processing by CACNA1C and ANK3 risk 
genes for bipolar disorder. JAMA Psychiatry 2013; 
70: 1303-1311.
18) Ota M, Hori H, Sato N, Yoshida F, Hattori K, Te-
raishi T, Kunugi H. The effects of ankyrin 3 gene 
risk variants on brain structures in patients with 
bipolar disorder and healthy subjects. Psychiatry 
Clin Neurosci 2016; 70: 498-506.
19) Rizzo LB, Costa LG, Mansur RB, Swardfager W, 
Belangero SI, Grassi-Oliveira R, McIntyre RS, 
Bauer ME, Brietzke E. The theory of bipolar di-
sorder as an illness of accelerated aging: impli-
G. Kalcev, A. Preti, A. Scano, G. Orrù, M.G. Carta 
5718
cations for clinical care and research. Neurosci 
Biobehav Rev 2014; 42: 157-169.
20) Cichon S, Mühleisen TW, Degenhardt FA, Mat-
theisen M, Miró X, Strohmaier J, Steffens M, 
Meesters C, Herms S, Weingarten M, Priebe L, 
Haenisch B, Alexander M, Vollmer J, Breuer R, 
Schmäl C, Tessmann P, Moebus S, Wichmann 
HE, Schreiber S, Müller-Myhsok B, Lucae S, Ja-
main S, Leboyer M, Bellivier F, Etain B, Henry C, 
Kahn JP, Heath S; Bipolar Disorder Genome Stu-
dy (BiGS) Consortium, Hamshere M, O’Donovan 
MC, Owen MJ, Craddock N, Schwarz M, Vedder 
H, Kammerer-Ciernioch J, Reif A, Sasse J, Bauer 
M, Hautzinger M, Wright A, Mitchell PB, Schofield 
PR, Montgomery GW, Medland SE, Gordon SD, 
Martin NG, Gustafsson O, Andreassen O, Djuro-
vic S, Sigurdsson E, Steinberg S, Stefansson H, 
Stefansson K, Kapur-Pojskic L, Oruc L, Rivas F, 
Mayoral F, Chuchalin A, Babadjanova G, Tiganov 
AS, Pantelejeva G, Abramova LI, Grigoroiu-Ser-
banescu M, Diaconu CC, Czerski PM, Hauser J, 
Zimmer A, Lathrop M, Schulze TG, Wienker TF, 
Schumacher J, Maier W, Propping P, Rietschel 
M, Nöthen MM. Genome-wide association study 
identifies genetic variation in neurocan as a su-
sceptibility factor for bipolar disorder. Am J Hum 
Genet 2011; 88: 372-381. 
21) Schultz CC, Mühleisen TW, Nenadic I, Koch K, 
Wagner G, Schachtzabel C, Siedek F, Nöthen 
MM, Rietschel M, Deufel T, Kiehntopf M, Cichon 
S, Reichenbach JR, Sauer H, Schlösser RG. 
Common variation in NCAN, a risk factor for bi-
polar disorder and schizophrenia, influences lo-
cal cortical folding in schizophrenia. Psychol Med 
2014; 44: 811-820. 
22) Duman RS, Monteggia LM. A neurotrophic model 
for stress-related mood disorders. Biol Psychiatry 
2006; 59: 1116-1127.
23) Notaras M, Hill R, van den Buuse M. The BDNF 
gene Val66Met polymorphism as a modifier of 
psychiatric disorder susceptibility: progress and 
controversy. Mol Psychiatry 2015; 20: 916-930. 
24) Cao B, Bauer IE, Sharma AN, Mwangi B, Frazier 
T, Lavagnino L, Zunta-Soares GB, Walss-Bass C, 
Glahn DC, Kapczinski F, Nielsen DA, Soares JC. 
Reduced hippocampus volume and memory per-
formance in bipolar disorder patients carrying the 
BDNF val66met met allele. J Affect Disord 2016; 
198: 198-205. 
25) Kim B, Kim C, Hong J, Kim S, Lee C, Joo Y. 
Brain-derived neurotrophic factor Val/Met poly-
morphism and bipolar disorder. Association of the 
met allele with suicidal behaviour of bipolar pa-
tients. Neuropsychobiology 2008; 58: 97-103.
26) McIntosh AM, Moorhead TW, McKirdy J, Sus-
smann JE, Hall J, Johnstone EC, Lawrie SM. 
Temporal grey matter reductions in bipolar disor-
der are associated with the BDNF Val66Met poly-
morphism. Mol Psychiatry 2007; 12: 902-903.
27) Fernandes BS, Molendijk ML, Kohler CA, Soares 
JC, Leite CM, Machado-Vieira R, Ribeiro TL, Silva 
JC, Sales PM, Quevedo J, Oertel-Knochel V, Vie-
ta E, Gonzalez-Pinto A, Berk M, Carvalho AF. Pe-
ripheral brain-derived neurotrophic factor (BDNF) 
as a biomarker in bipolar disorder: a meta-analy-
sis of 52 studies. BMC Medicine 2015; 30: 289.
28) D’Addario C, Dell’Osso B, Palazzo MC, Benatti 
B, Lietti L, Cattaneo E, Galimberti D, Fenoglio C, 
Cortini F, Scarpini E, Arosio B, Di Francesco A, 
Di Benedetto M, Romualdi P, Candeletti S, Mari 
D, Bergamaschini L, Bresolin N, Maccarrone M, 
Altamura AC. Selective DNA methylation of BDNF 
promoter in bipolar disorder: differences among 
patients with BDI and BDII. Neuropsychopharma-
cology 2012; 37: 1647-1655.
29) Savitz J, van der Merwe L, Newman TK, Stein 
DJ, Ramesar R. Catechol-o-methyltransferase 
genotype and childhood trauma may interact to 
impact schizotypal personality traits. Behav Ge-
net 2010; 40: 415-423.
30) Dickerson FB, Boronow JJ, Stallings C, Origo-
ni AE, Cole S, Leister F, Krivogorsky B, Yolken 
RH. The catechol Omethyltransferase Val158Met 
polymorphism and herpes simplex virus type 1 
infection are risk factors for cognitive impairment 
in bipolar disorder: additive gene-environmental 
effects in a complex human psychiatric disorder. 
Bipolar Disord 2006; 8: 124-132.
31) Benedetti F, Riccaboni R, Poletti S, Radaelli D, 
Locatelli C, Lorenzi C, Pirovano A, Smeraldi E, 
Colombo C. The serotonin transporter genotype 
modulates the relationship between early stress 
and adult suicidality in bipolar disorder. Bipolar 
Disord 2014; 16: 857-866. 
32) Shah MP, Wang F, Kalmar JH, Chepenik LG, Tie 
K, Pittman B, Jones MM, Constable RT, Gelernter 
J, Blumberg HP. Role of variation in the serotonin 
transporter protein gene (SLC6A4) in trait distur-
bances in the ventral anterior cingulate in bipolar 
disorder. Neuropsychopharmacology 2009; 34: 
1301-1310.
33) Mei L, Nave KA. Neuregulin-ERBB signaling in 
the nervous system and neuropsychiatric disea-
ses. Neuron 2014; 83: 27-49.
34) Cannon DM, Walshe M, Dempster E, Collier DA, 
Marshall N, Bramon E, Murray RM, McDonald C. 
The association of white matter volume in psycho-
tic disorders with genotypic variation in NRG1, 
MOG and CNP: a voxelbased analysis in affected 
individuals and their unaffected relatives. Transla-
tional Psychiatry 2012; 2: e167.
35) Donohoe G, Morris DW, Corvin A. The psychosis 
susceptibility gene ZNF804A: associations, fun-
ctions, and phenotypes. Schizophr Bull 2010; 36: 
904-909.
36) Lett TA, Zai CC, Tiwari AK, Shaikh SA, Likhodi 
O, Kennedy JL, Muller DJ. ANK3, CACNA1C and 
ZNF804A gene variants in bipolar disorders and 
psychosis subphenotype. World J Biol Psychiatry 
2011; 12: 392-397.
37) Williams HJ, Norton N, Dwyer S, Moskvina V, 
Nikolov I, Carroll L, Georgieva L, Williams NM, 
Morris DW, Quinn EM, Giegling I, Ikeda M, Wood 
J, Lencz T, Hultman C, Lichtenstein P, Thiselton D, 
Insight into susceptibility genes associated with bipolar disorder: a systematic review
5719
Maher BS; Molecular Genetics of Schizophrenia 
Collaboration (MGS) International Schizophrenia 
Consortium (ISC), SGENE-plus, GROUP, Malho-
tra AK, Riley B, Kendler KS, Gill M, Sullivan P, 
Sklar P, Purcell S, Nimgaonkar VL, Kirov G, Hol-
mans P, Corvin A, Rujescu D, Craddock N, Owen 
MJ, O’Donovan MC. Fine mapping of ZNF804A 
and genome-wide significant evidence for its in-
volvement in schizophrenia and bipolar disorder. 
Mol Psychiatry 2011; 16: 429-441.
38) Jimerson DC, Post RM, Carman JS, van Kammen 
DP, Wood JH, Goodwin FK, Bunney WE Jr. CSF 
calcium: clinical correlates in affective illness and 
schizophrenia. Biol Psychiatry 1979; 14: 37-51.
39) Ferreira MA, O’Donovan MC, Meng YA, Jones IR, 
Ruderfer DM, Jones L, Fan J, Kirov G, Perlis RH, 
Green EK, Smoller JW, Grozeva D, Stone J, Niko-
lov I, Chambert K, Hamshere ML, Nimgaonkar 
VL, Moskvina V, Thase ME, Caesar S, Sachs GS, 
Franklin J, Gordon-Smith K, Ardlie KG, Gabriel 
SB, Fraser C, Blumenstiel B, Defelice M, Breen 
G, Gill M, Morris DW, Elkin A, Muir WJ, McGhee 
KA, Williamson R, MacIntyre DJ, MacLean AW, St 
CD, Robinson M, Van Beck M, Pereira AC, Kan-
daswamy R, McQuillin A, Collier DA, Bass NJ, 
Young AH, Lawrence J, Ferrier IN, Anjorin A, Far-
mer A, Curtis D, Scolnick EM, McGuffin P, Daly 
MJ, Corvin AP, Holmans PA, Blackwood DH, Gur-
ling HM, Owen MJ, Purcell SM, Sklar P, Craddock 
N; Wellcome Trust Case Control Consortium. 
Collaborative genome-wide association analysis 
supports a role for ANK3 and CACNA1C in bipolar 
disorder. Nat Genet 2008; 40: 1056-1058.
40) Ament SA, Szelinger S, Glusman G, Ashworth 
J, Hou L, Akula N, Shekhtman T, Badner JA, 
Brunkow ME, Mauldin DE, Stittrich AB, Roule-
au K, Detera-Wadleigh SD, Nurnberger JI Jr, 
Edenberg HJ, Gershon ES, Schork N; Bipolar 
Genome Study, Price ND, Gelinas R, Hood L, 
Craig D, McMahon FJ, Kelsoe JR, Roach JC. 
Rare variants in neuronal excitability genes in-
fluence risk for bipolar disorder. Proc Natl Acad 
Sci USA 2015; 112: 3576-3581.
41) Harvey AG. Sleep and circadian rhythms in bi-
polar disorder: seeking synchrony, harmony, and 
regulation. Am J Psychiatry 2008; 165: 820-829.
42) J, Quinn EM, Schulze TG, Williams NM, Giegling I, 
Iwata N, Ikeda M, Darvasi A, Shifman S, He L, Duan 
J, Sanders AR, Levinson DF, Gejman PV, Cichon 
S, Nöthen MM, Gill M, Corvin A, Rujescu D, Kirov 
G, Owen MJ, Buccola NG, Mowry BJ, Freedman 
R, Amin F, Black DW, Silverman JM, Byerley WF, 
Cloninger CR, Molecular Genetics of Schizophrenia 
Collaboration. Identification of loci associated with 
schizophrenia by genome-wide association and fol-
low-up. Nat Genet 2008; 40: 1053-1055.
43) Dell’Osso B, D’Addario C, Carlotta Palazzo M, 
Benatti B, Camuri G, Galimberti D, Fenoglio C, 
Scarpini E, Di Francesco A, Maccarrone M, Alta-
mura AC. Epigenetic modulation of BDNF gene: 
differences in DNA methylation between unipolar 
and bipolar patients. J Affect Disord 2014; 166: 
330-333.
44) Chen DC, Wang J, Wang B, Yang SC, Zhang CX, 
Zheng YL, Li YL, Wang N, Yang KB, Xiu MH, Ko-
sten TR, Zhang XY. Decreased levels of serum 
brain-derived neurotrophic factor in drug-naïve 
first-episode schizophrenia: relationship to clini-
cal phenotypes. Psychopharmacology 2009; 207: 
375-380.
45) Carrard A, Salzmann A, Malafosse A, Karege 
F. Increased DNA methylation status of the se-
rotonin receptor 5HTR1A gene promoter in schi-
zophrenia and bipolar disorder. J Affect Disord 
2011; 132: 450-453. 
46) Bellivier F, Chaste P, Malafosse A. Association 
between the TPH gene A218C polymorphism and 
suicidal behaviour: a metanalysis. Am J Med Ge-
net B Neuropsychiatr Genet 2004; 124B: 87-91.
47) Zill P, Büttner A, Eisenmenger W, Möller H, Bondy 
B, Ackenheil M. Single nucleotide polymorphism 
and haplotype analysis of a novel tryptophan hy-
droxylase isoform (TPH2) gene in suicide victims. 
Biol Psychiatry 2004; 56: 581-586.
48) Samadi Rad B, Ghasemi A, Seifi M, Samadiku-
chaksaraei A, Baybordi F, Danaei N. Serotonin 
1A receptor genetic variations, suicide, and life 
events in the Iranian population. Psychiatry Clin 
Neurosci 2012; 66: 337-343.
49) Magno LA, Miranda DM, Neves FS, Pimenta GJ, 
Mello MP, De Marco LA, Correa H, Romano-Sil-
va MA. Association between AKT1 but not AKTIP 
genetic variants and increased risk for suicidal 
behavior in bipolar patients. Genes Brain Behav 
2010; 9: 411-418.
50) Jiménez E, Arias B, Mitjans M, Goikolea JM, Roda 
E, Ruíz V, Pérez A, Sáiz PA, García-Portilla MP, 
Burón P, Bobes J, Vieta E, Benabarre A. Associa-
tion between GSK3β gene and increased impulsi-
vity in bipolar disorder. Eur Neuropsychopharma-
col 2014; 24: 510-518.
51) Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, 
Tamminga CA, Pandey GN. Altered gene expres-
sion of brain-derived neurotrophic factor and recep-
tor tyrosine kinase B in postmortem brain of suicide 
subjects. Arch Gen Psychiatry 2003; 60: 804-815.
52) Sequeira A, Mamdani F, Lalovic A, Anguelova M, 
Lesage A, Seguin M, Chawky N, Desautels A, Tu-
recki G. Alpha 2A adrenergic receptor gene and 
suicide. Psychiatry Res 2004; 125: 87-93.
53) Ono H, Shirakawa O, Nushida H, Ueno Y, Maeda 
K. Association between cathecol-O-methyltran-
sferase functional polymorphism and male suici-
de completers. Neuropsychopharmacology 2004; 
75: 807-821.
54) Tang J, Xiao L, Shu C, Wang G, Liu Z, Wang X, 
Wang H, Bai X. Association of the brain-derived 
neurotrophic factor gene and bipolar disorder with 
early age of onset in mainland China. Neurosci 
Lett 2008; 433: 98-102.
55) Squassina A, Manchia M, Costa M, Chillotti C, Ar-
dau R, Del Zompo M, Severino G. Age at onset in 
bipolar disorder: Investigation of the role of TaqIA 
polymorphism of DRD2 gene in a Sardinian sam-
ple. Eur Psychiatry 2011; 26: 141-143.
G. Kalcev, A. Preti, A. Scano, G. Orrù, M.G. Carta 
5720
56) Leszczyńska-Rodziewicz A, Hauser J, Dmitrza-
k-Weglarz M, Skibińka M, Czerski P, Zakrzewska 
A, Kosmowska M, Rybakowski JK. Lack of as-
sociation between polymorphisms of dopamine 
receptors, type D2, and bipolar affective illness 
in a Polish population. Med Sci Monit 2005; 11: 
CR289-295.
57) Massat I, Kocabas NA, Crisafulli C, Chiesa A, Ca-
lati R, Linotte S, Kasper S, Fink M, Antonijevic I, 
Forray C, Snyder L, Bollen J, Zohar J, De Ronchi 
D, Souery D, Serretti A, Mendlewicz J. COMT and 
age at onset in mood disorders: a replication and 
extension study. Neurosci Lett 2011; 498: 218-221.
58) Zhang Z, Lindpaintner K, Che R, He Z, Wang P, 
Yang P, Feng G, He L, Shi Y. The Val/Met functio-
nal polymorphism in COMT confers susceptibility 
to bipolar disorder: evidence from an associa-
tion study and a meta-analysis. J Neural Transm 
2009; 116: 1193-1200.
59) Oliveira J, Hamdani N, Busson M, Etain B, Benna-
bi M, Amokrane K, Boukouaci W, Fortier C, Mar-
zais F, Bengoufa D, Bellivier F, Henry C, Kahn JP, 
Charron D, Krishnamoorthy R, Le Corvoisier P, Le-
boyer M, Tamouza R. Association between toll-like 
receptor 2 gene diversity and early-onset bipolar 
disorder. J Affect Disord 2014; 165: 135-141.
60) Oliveira J, Busson M, Etain B, Jamain S, Hamda-
ni N, Boukouaci W, Amokrane K, Bennabi M, Le 
Guen E, Dargél AA, Houenou J, Ivanova R, Belli-
vier F, Henry C, Kahn JP, Charron D, Krishnamo-
orthy R, Vervoitte L, Leboyer M, Tamouza R. Poly-
morphism of Toll-like receptor 4 gene in bipolar 
disorder. J Affect Disord 2014; 152-154: 395-402.
61) Psychiatric GWAS Consortium Bipolar Disorder 
Working Group. Large-scale genome-wide as-
sociation analysis of bipolar disorder identifies a 
new susceptibility locus near ODZ4. Nat Genet 
2011; 43: 977-983.
62) Goodwin FK, Jamison KR. Manic-Depressive 
Illness. Second. Oxford University Press; New 
York 2007; 126.
63) Sinclair D, Fillman SG, Webster MJ, Weickert CS. 
Dysregulation of glucocorticoid receptor co-fac-
tors FKBP5, BAG1 and PTGES3 in prefrontal cor-
tex in psychotic illness. Sci Rep 2013; 3: 3539.
64) Cantoni GL. S-Anenysylmethionine: a new inter-
mediate formed enzymatically from 1-methionine 
and adenosine triphosphate. J Biol Chem 1953; 
204: 403-416.
65) El-Hadidy MA, Abdeen HM, Abd El-Aziz SM, 
Al-Harrass M. MTHFR gene polymorphism and 
age of onset of schizophrenia and bipolar disor-
der. Biomed Res Int 2014; 2014: 318483. 
66) Ou J, Li M, Xiao X. The schizophrenia susceptibi-
lity gene ZNF804A confers risk of major mood di-
sorders. World J Biol Psychiatry 2017; 18: 557-562.
67) Misiak B, Stramecki F, Gawęda Ł, Prochwicz K, 
Sąsiadek MM, Moustafa AA, Frydecka D. Inte-
ractions Between Variation in Candidate Genes 
and Environmental Factors in the Etiology of Schi-
zophrenia and Bipolar Disorder: a Systematic Re-
view. Mol Neurobiol 2018; 55: 5075-5100.
68) Mühleisen TW, Leber M, Schulze TG, Strohma-
ier J, Degenhardt F, Treutlein J, Mattheisen M, 
Forstner AJ, Schumacher J, Breuer R, Meier S, 
Herms S, Hoffmann P, Lacour A, Witt SH, Reif A, 
Müller-Myhsok B, Lucae S, Maier W, Schwarz M, 
Vedder H, Kammerer-Ciernioch J, Pfennig A, Bau-
er M, Hautzinger M, Moebus S, Priebe L, Czerski 
PM, Hauser J, Lissowska J, Szeszenia-Dabrowska 
N, Brennan P, McKay JD, Wright A, Mitchell PB, 
Fullerton JM, Schofield PR, Montgomery GW, 
Medland SE, Gordon SD, Martin NG, Krasnow V, 
Chuchalin A, Babadjanova G, Pantelejeva G, Abra-
mova LI, Tiganov AS, Polonikov A, Khusnutdinova 
E, Alda M, Grof P, Rouleau GA, Turecki G, Laprise 
C, Rivas F, Mayoral F, Kogevinas M, Grigoroiu-Ser-
banescu M, Propping P, Becker T, Rietschel M, 
Nöthen MM, Cichon S. Genome-wide association 
study reveals two new risk loci for bipolar disorder. 
Nat Commun 2015; 5: 3339.
69) De Luca V, Likhodi O, Van Tol HH, Kennedy 
JL, Wong AH. Tryptophan hydroxylase 2 gene 
expression and promoter polymorphisms in bipo-
lar disorder and schizophrenia. Psychopharma-
cology 2005; 183: 378-382.
70) Shao L, Vawter MP. Shared Gene Expression Al-
terations in Schizophrenia and Bipolar Disorder. 
Biol Psychiatry 2008; 64: 89-97.
71) Poletti S, Aggio V, Bollettini I, Falini A, Colombo 
C, Benedetti F. SREBF-2 polymorphism influen-
ces white matter microstructure in bipolar disor-
der. Psychiatry Res Neuroimaging 2016; 257: 39-
46.
72) Benedetti F, Bollettini I, Poletti S, Locatelli C, 
Lorenzi C, Pirovano A, Smeraldi E, Colombo C. 
White matter microstructure in bipolar disorder is 
influenced by the serotonin transporter gene poly-
morphism 5-HTTLPR. Genes Brain Behav 2015; 
14: 238-250.
73) Klimek V, Rajkowska G, Luker SN, Dilley G, Mel-
tzer HY, Overholser JC, Stockmeier CA, Ordway 
GA. Brain noradrenergic receptors in major de-
pression and schizophrenia. Neuropsychophar-
macology 1999; 21: 69-81.
74) McCarthy MJ, Leckband SG, Kelsoe JR. Pharma-
cogenetics of lithium response in bipolar disorder. 
Pharmacogenomics 2010; 11: 1439-1465.
75) Mamdani F, Alda M, Grof P, Young LT, Rouleau G, 
Turecki G. Lithium response and genetic variation 
in the CREB family of genes. Am J Med Genet B 
Neuropsychiatr Genet 2008; 147: 500-504.
76) Squassina A, Costa M, Congiu D, Manchia M, An-
gius A, Deiana V, Ardau R, Chillotti C, Severino G, 
Calza S, Del Zompo M. Insulin-like growth factor 1 
(IGF-1) expression is up-regulated in lymphobla-
stoid cell lines of lithium responsive bipolar disor-
der patients. Pharmacol Res 2013; 73: 1-7.
77) Kretschmer T, England JD, Happel LT, Liu ZP, 
Thouron CL, Nguyen DH, Beuerman RW, Kline 
DG. Ankyrin G and voltage gated sodium chan-
nels colocalize in human neuroma-key proteins of 
membrane remodeling after axonal injury. Neuro-
sci Lett 2002; 323: 151-155.
Insight into susceptibility genes associated with bipolar disorder: a systematic review
5721
78) Cardno AG, Marshall EJ, Coid B, Macdonald AM, 
Ribchester TR, Davies NJ. Heritability estimates for 
psychotic disorders: the Maudsley twin psychosis 
series. Arch Gen Psychiatry 1999; 56: 162-168. 
79) McMahon FJ, Stine OC, Meyers DA, Simpson SG, 
DePaulo JR. Patterns of maternal transmission in 
bipolar affective disorder. Am J Hum Genet 1995; 
56: 1277-1286.
80) Calati R, Crisafulli C, Balestri M, Serretti A, Spina 
E, Calabrò M, Sidoti A, Albani D, Massat I, Höfer 
P, Amital D, Juven-Wetzler A, Kasper S, Zohar J, 
Souery D, Montgomery S, Mendlewicz J. Evaluation 
of the role of MAPK1 and CREB1 polymorphisms 
on treatment resistance, response and remission in 
mood disorder patients. Prog Neuropsychopharma-
col Biol Psychiatry 2013; 44: 271-278.
81) Lu B, Nagappan G, Lu Y. BDNF and synaptic pla-
sticity, cognitive function, and dysfunction. Handb 
Exp Pharmacol 2014; 220: 223-250.
82) Miyake N, Thompson J, Skinbjerg M, Abi-Dar-
gham A. Presynaptic dopamine in schizophrenia. 
CNS Neurosci Ther 2011; 17: 104-109.
83) Serretti A, Drago A, De Ronchi D. HTR2A gene 
variants and psychiatric disorders: a review of 
current literature and selection of SNPs for future 
studies. Curr Med Chem 2007; 14: 2053-2069.
84) Antypa N, Drago A, Serretti A. The role of COMT 
gene variants in depression: bridging neurop-
sychological, behavioral and clinical phenotypes. 
Neurosci Biobehav Rev 2013; 37: 1597-1610.
85) Fabbri C, Crisafulli C, Calati R, Albani D, Forlo-
ni G, Calabro M, Martines R, Kasper S, Zohar J, 
Juven-Wetzler A, Souery D, Montgomery S, Men-
dlewicz J, Serretti A. Neuroplasticity and second 
messenger pathways in antidepressant efficacy: 
pharmacogenetic results from a prospective 
trial investigating treatment resistance. Eur Arch 
Psychiatry Clin Neurosci 2017; 267: 723-735.
86) Stelzer G, Rosen N, Plaschkes I, Zimmerman S, 
Twik M, Fishilevich S, Stein TI, Nudel R, Lieder 
I, Mazor Y, Kaplan S, Dahary D, Warshawsky D, 
Guan-Golan Y, Kohn A, Rappaport N, Safran M, 
Lancet D. The GeneCards suite: from gene data 
mining to disease genome sequence analyses. 
Curr Protoc Bioinform 2016; 54: 1.30.1-1.30.33. 
87) Seifuddin F, Pirooznia M, Judy JT, Goes FS, Po-
tash JB, Zandi PP. Systematic review of geno-
me-wide gene expression studies of bipolar di-
sorder. BMC Psychiatry 2013; 13: 213.
88) Yoshimizu T, Pan JQ, Mungenast AE, Madison 
JM, Su S, Ketterman J, Ongur D, McPhie D, 
Cohen B, Perlis R, Tsai LH. Functional implica-
tions of a psychiatric risk variant within CACNA1C 
in induced human neurons. Mol Psychiatry 2015; 
20: 284.
89) Bird A. DNA methylation patterns and epigenetic 
memory. Genes Dev 2002; 16: 6-21.
90) Green M, Matheson S, Shepherd A, Weickert C, 
Carr V. Brain-derived neurotrophic factor levels in 
schizophrenia: a systematic review with meta-a-
nalysis. Mol Psychiatry 2010; 16: 960-972.
91) Plans L, Barrot C, Nieto E, Rios J, Schulze TG, 
Papiol S, Mitjans M, Vieta E, Benabarre A. As-
sociation between completed suicide and bipolar 
disorder: A systematic review of the literature. J 
Affect Disord 2019; 242: 111-122.
92) Belvederi Murri M, Prestia D, Mondelli V, Pariante 
C, Patti S, Olivieri B, Arzani C, Masotti M, Respi-
no M, Antonioli M, Vassallo L, Serafini G, Perna 
G, Pompili M, Amore M. The HPA axis in bipolar 
disorder: Systematic review and meta-analysis. 
Psychoneuroendocrinology 2016; 63: 327-342.
93) Gao J, Jia M, Qiao D, Qiu H, Sokolove J, Zhang 
J, Pan Z. TPH2 gene polymorphisms and bipo-
lar disorder: A meta-analysis. Am J Med Genet B 
Neuropsychiatr Genet 2016; 171B: 145-152.
94) Sun Y, Hu D, Liang J, Bao YP, Meng SQ, Lu L, 
Shi J. Association between variants of zinc fin-
ger genes and psychiatric disorders: systematic 
review and meta-analysis. Schizophr Res 2015; 
162: 124-137.
95) Viswanath B, Jose SP, Squassina A, Thirthalli J, 
Purushottam M, Mukherjee O, Vladimirov V, Pa-
trinos GP, Del Zompo M, Jain S. Cellular models 
to study bipolar disorder: A systematic review. J 
Affect Disord 2015; 184: 36-50.
96) Buoli M, Caldiroli A, Cumerlato Melter C, Serati 
M, de Nijs J, Altamura AC. Biological aspects and 
candidate biomarkers for psychotic bipolar disor-
der: A systematic review. Psychiatry Clin Neuro-
sci 2016; 70: 227-244.
97) Cipriani A, Saunders K, Attenburrow MJ, Stefa-
niak J, Panchal P, Stockton S, Lane TA, Tunbridge 
EM, Geddes JR, Harrison PJ. A systematic review 
of calcium channel antagonists in bipolar disorder 
and some considerations for their future develop-
ment. Mol Psychiatry 2016; 21: 1324-1332.
98) Teroganova N, Girshkin L, Suter CM, Green MJ. 
DNA methylation in peripheral tissue of schi-
zophrenia and bipolar disorder: a systematic re-
view. BMC Genet 2016; 17: 27.
99) Amare AT, Schubert KO, Klingler-Hoffmann M, 
Cohen-Woods S, Baune BT. The genetic overlap 
between mood disorders and cardiometabolic di-
seases: a systematic review of genome wide and 
candidate gene studies. Transl Psychiatry 2017; 7: 
e1007.
100) Pereira LP, Köhler CA, de Sousa RT, Solmi M, 
de Freitas BP, Fornaro M, Machado-Vieira R, 
Miskowiak KW, Vieta E, Veronese N, Stubbs B, 
Carvalho AF. The relationship between genetic 
risk variants with brain structure and function in 
bipolar disorder: A systematic review of gene-
tic-neuroimaging studies. Neurosci Biobehav 
Rev 2017; 79: 87-109.
101) Roby Y. ANK3 gene polymorphisms and bipolar 
disorder: a meta-analysis. Psychiatr Genet 2017; 
27: 225-235.
102) Cruz ACP, Ferrasa A, Muotri AR, Herai RH. Fre-
quency and association of mitochondrial genetic 
variants with neurological disorders. Mitochon-
drion 2019; 46: 345-360.
G. Kalcev, A. Preti, A. Scano, G. Orrù, M.G. Carta 
5722
103) Ikeda M, Saito T, Kondo K, Iwata N. Genome-wi-
de association studies of bipolar disorder: A sy-
stematic review of recent findings and their clini-
cal implications. Psychiatry Clin Neurosci 2018; 
72: 52-63. 
104) Rao S, Han X, Shi M, Siu CO, Waye MMY, Liu 
G, Wing YK. Associations of the serotonin tran-
sporter promoter polymorphism (5-HTTLPR) 
with bipolar disorder and treatment response: A 
systematic review and meta-analysis. Prog Neu-
ropsychopharmacol Biol Psychiatry 2019; 89: 
214-226.
105) Routhieaux M, Keels J, Tillery EE. The use of 
pharmacogenetic testing in patients with schi-
zophrenia or bipolar disorder: A systematic re-
view. Ment Health Clin 2018; 8: 294-302. 
106) Kennedy KP, Cullen KR, DeYoung CG, Kli-
mes-Dougan B. The genetics of early-onset bi-
polar disorder: A systematic review. J Affect Di-
sord 2015; 184: 1-12.
107) Bowie CR, Depp C, McGrath JA, Wolyniec P, 
Mausbach BT, Thornquist MH, Luke J, Patterson 
TL, Harvey PD, Pulver AE. Prediction of real-wor-
ld functional disability in chronic mental disor-
ders: a comparison of schizophrenia and bipolar 
disorder. Am J Psychiatry 2010; 167: 1116-1124.
108) Badner JA, Gershon ES. Meta-analysis of who-
le-genome linkage scans of bipolar disorder and 
schizophrenia. Mol Psychiatry 2002; 7: 405-411.
109) Carta MG, Angst J. Screening for bipolar disor-
ders: A public health issue. J Affect Disord 2016; 
205: 139-143.
110) Orrù G, Carta MG. Genetic Variants Involved 
in Bipolar Disorder, a Rough Road Ahead. Clin 
Pract Epidemiol Ment Health 2018; 28: 37-45.
111) Carta MG, Angst J. Epidemiological and clinical 
aspects of bipolar disorders: controversies or a 
common need to redefine the aims and methodo-
logical aspects of surveys. Clin Pract Epidemiol 
Ment Health 2005; 1: 4.
112) de Sá AS, Campos C, Rocha NB, Yuan TF, Paes 
F, Arias-Carrión O, Carta MG, Nardi AE, Che-
niaux E, Machado S. Neurobiology of Bipolar Di-
sorder: Abnormalities on Cognitive and Cortical 
Functioning and Biomarker Levels. CNS Neurol 
Disord Drug Targets 2016; 15: 713-722.
113) Kurtz MM, Gerraty RT. A meta-analytic investi-
gation of neurocognitive deficits in bipolar illness: 
profile and effects of clinical state. Neuropsycho-
logy 2009; 23: 551-562.
114) Bora E. Differences in cognitive impairment 
between schizophrenia and bipolar disorder: 
Considering the role of heterogeneity. Psychiatry 
Clin Neurosci 2016; 70: 424-433.
115) Arts B, Jabben N, Krabbendam L, van Os J. Me-
ta-analyses of cognitive functioning in euthymic 
bipolar patients and their first-degree relatives. 
Psychol Med 2008; 38: 771-785.
116) Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson 
P, Meltzer HY. Characterization of typical and 
atypical antipsychotic drugs based on in vivo oc-
cupancy of serotonin2 and dopamine2 receptors. 
J Pharmacol Exp Ther 1993; 266: 1374-1384.
117) Noor A, Lionel AC, Cohen-Woods S, Moghimi 
N, Rucker J, Fennell A, Thiruvahindrapuram B, 
Kaufman L, Degagne B, Wei J, Parikh SV, Muglia 
P, Forte J, Scherer SW, Kennedy JL, Xu W, Mc-
Guffin P, Farmer A, Strauss J, Vincent JB. Copy 
number variant study of bipolar disorder in Ca-
nadian and UK populations implicates synaptic 
genes. Am J Med Genet B 2014; 165B: 303-313.
118) Qesseveur G, Petit AC, Nguyen HT, Dahan L, 
Colle R, Rotenberg S, Seif I, Robert P, David D, 
Guilloux JP, Gardier AM, Verstuyft C, Becque-
mont L, Corruble E, Guiard BP. Genetic dysfun-
ction of serotonin 2A receptor hampers response 
to antidepressant drugs: a translational approa-
ch. Neuropharmacology 2016; 105: 142-153.
119) International Schizophrenia Consortium, Purcell 
SM, Wray NR, Stone JL, Visscher PM, O’Dono-
van MC, Sullivan PF, Sklar P. Common polygenic 
variation contributes to risk of schizophrenia and 
bipolar disorder. Nature 2009; 460: 748-752.
120) Zhang D, Cheng L, Qian Y, Alliey-Rodriguez N, 
Kelsoe JR, Greenwood T, Nievergelt C, Barrett TB, 
McKinney R, Schork N, Smith EN, Bloss C, Nurn-
berger J, Edenberg HJ, Foroud T, Sheftner W, Law-
son WB, Nwulia EA, Hipolito M, Coryell W, Rice J, 
Byerley W, McMahon F, Schulze TG, Berrettini W, 
Potash JB, Belmonte PL, Zandi PP, McInnis MG, 
Zöllner S, Craig D, Szelinger S, Koller D, Christian 
SL, Liu C, Gershon ES. Singleton deletions throu-
ghout the genome increase risk of bipolar disorder. 
Mol Psychiatry 2009; 14: 376-380.
121) Lemaitre RN, Tanaka T, Tang W, Manichaikul A, 
Foy M, Kabagambe EK, Nettleton JA, King IB, 
Weng LC, Bhattacharya S, Bandinelli S, Bis JC, 
Rich SS, Jacobs DR Jr, Cherubini A, McKnight 
B, Liang S, Gu X, Rice K, Laurie CC, Lumley T, 
Browning BL, Psaty BM, Chen YD, Friedlander 
Y, Djousse L, Wu JH, Siscovick DS, Uitterlinden 
AG, Arnett DK, Ferrucci L, Fornage M, Tsai MY, 
Mozaffarian D, Steffen LM. Genetic loci associa-
ted with plasma phospholipid n-3 fatty acids: a 
meta-analysis of genome-wide association stu-
dies from the CHARGE Consortium. PLoS Genet 
2011; 7: e1002193.
122) Lok A, Bockting CL, Koeter MW, Snieder H, As-
sies J, Mocking RJ, Vinkers CH, Kahn RS, Boks 
MP, Schene AH. Interaction between the MTHFR 
C677T polymorphism and traumatic childhood 
events predicts depression. Transl Psychiatry 
2013; 30: e288.
123) Cross-Disorder Group of the Psychiatric Genomics 
Consortium. Identification of risk loci with shared 
effects on five major psychiatric disorders: a geno-
me-wide analysis. Lancet 2013; 381: 1371-1379. 
124) McDonald ML, MacMullen C, Liu DJ, Leal SM, 
Davis RL. Genetic association of cyclic AMP 
signaling genes with bipolar disorder. Transl 
Psychiatry 2012; 2: e169.
125) Winham SJ, Cuellar-Barboza AB, Oliveros A, 
McElroy SL, Crow S, Colby C, Choi DS, Chauhan 
Insight into susceptibility genes associated with bipolar disorder: a systematic review
5723
M, Frye M, Biernacka JM. Genome-wide associa-
tion study of bipolar disorder accounting for effect 
of body mass index identifies a new risk allele in 
TCF7L2. Mol Psychiatry 2014; 19: 1010-1016.
126) López-Figueroa AL, Norton CS, López-Figueroa 
MO, Armellini-Dodel D, Burke S, Akil H, López 
JF, Watson SJ. Serotonin 5-HT1A, 5-HT1B, and 
5-HT2A receptor mRNA expression in subjects 
with major depression, bipolar disorder, and schi-
zophrenia. Biol Psychiatry 2004; 55: 225-233.
127) Finseth PI, Sønderby IE, Djurovic S, Agartz I, 
Malt UF, Melle I, Morken G, Andreassen OA, Va-
aler AE, Tesli M. Association analysis between 
suicidal behaviour and candidate genes of bipo-
lar disorder and schizophrenia. J Affect Disord 
2014; 163: 110-114.
128) Finseth PI, Sønderby IE, Djurovic S, Agartz I, 
Malt UF, Melle I, Morken G, Andreassen OA, Va-
aler AE, Tesli M. Association analysis between 
suicidal behaviour and candidate genes of bipo-
lar disorder and schizophrenia. J Affect Disord 
2014; 163: 110-114.
129) Sarchiapone M, Carli V, Roy A, Iacoviello L, Cuo-
mo C, Latella MC, di Giannantonio M, Janiri L, de 
Gaetano M, Janal MN. Association of polymor-
phism (Val66Met) of brain-derived neurotrophic 
factor with suicide attempts in depressed patien-
ts. Neuropsychobiology 2008; 57: 139-145.
130) Lachman HM, Pedrosa E, Petruolo OA, 
Cockerham M, Papolos A, Novak T et al. Incre-
ase in GSK3beta gene copy number variation 
in bipolar disorder. Am J Med Genet B Neurop-
sychiatr Genet 2007; 144B: 259-265.
131) Lohoff FW, Dahl JP, Ferraro TN, Arnold SE, 
Gallinat J, Sander T, Berrettini WH. Variations 
in the vesicular monoamine transporter 1 gene 
(VMAT1/SLC18A1) are associated with bipolar i 
disorder. Neuropsychopharmacology 2006; 31: 
2739-2747.
132) Roche S, Cassidy F, Zhao C, Badger J, Claffey 
E, Mooney L, Delaney C, Dobrin S, McKeon P. 
Candidate gene analysis of 21q22: support for 
S100B as a susceptibility gene for bipolar affecti-
ve disorder with psychosis. Am J Med Genet B 
Neuropsychiatr Genet 2007; 144B: 1094-1096.
133) Grover D, Verma R, Goes FS et al. Family-based 
association of YWHAH in psychotic bipolar disor-
der. Am J Med Genet B Neuropsychiatr Genet 
2009; 150B: 977-983.
134) Goes FS, Zandi PP, Miao K, McMahon FJ, Ste-
ele J, Willour VL, Mackinnon DF, Mondimore 
FM, Schweizer B, Nurnberger JI Jr, Rice JP, 
Scheftner W, Coryell W, Berrettini WH, Kelsoe 
JR, Byerley W, Murphy DL, Gershon ES, Bipolar 
Disorder Phenome Group, Depaulo JR Jr, McIn-
nis MG, Potash JB. Mood-incongruent psychotic 
features in bipolar disorder: familial aggregation 
and suggestive linkage to 2p11-q14 and 13q21-
33. Am J Psychiatry 2007; 164: 236-247.
135) Müller DJ, Zai CC, Shinkai T, Strauss J, Kenne-
dy JL. Association between the DAOA/G72 gene 
and bipolar disorder and meta-analyses in bipo-
lar disorder and schizophrenia. Bipolar Disord 
2011; 13: 198-207.
136) Kato T. Molecular genetics of bipolar disorder. 
Neurosci Res 2001; 40: 105-113.
137) Schloesser RJ, Huang J, Klein PS, Manji HK. 
Cellular plasticity cascades in the pathophysio-
logy and treatment of bipolar disorder. Neurop-
sychopharmacology 2008; 33: 110-133.
138) Lee KY, Ahn YM, Joo EJ, Chang JS, Kim YS. The 
association of DUSP6 gene with schizophrenia 
and bipolar disorder: its possible role in the deve-
lopment of bipolar disorder. Mol Psychiatry 2006; 
11: 425-426.
139) de Sousa RT, Loch AA, Carvalho AF, Bruno-
ni AR, Haddad MR, Henter ID, Zarate CA, Ma-
chado-Vieira R. Genetic Studies on the Tripar-
tite Glutamate Synapse in the Pathophysiology 
and Therapeutics of Mood Disorders. Neurop-
sychopharmacology 2017; 42: 787-800.
140) Sugawara H, Iwamoto K, Bundo M, Ueda J, 
Miyauchi T, Komori A, Kazuno A, Adati N, Ku-
sumi I, Okazaki Y, Ishigooka J, Kojima T, Kato 
T. Hypermethylation of serotonin transporter 
gene in bipolar disorder detected by epigenome 
analysis of discordant monozygotic twins. Transl 
Psychiatry 2011; 1: e24.
141) Souza RP, Romano-Silva MA, Lieberman JA, 
Meltzer HY, MacNeil LT, Culotti JG, Kennedy JL, 
Wong AH. Genetic association of the GDNF al-
pha-receptor genes with schizophrenia and cloza-
pine response. J Psychiatr Res 2010; 44: 700-706.
142) Tan ML, Dyck BA, Gabriele J, Daya RP, Tho-
mas N, Sookram C, Basu D, Ferro MA, Chong 
VZ, Mishra RK. Synapsin II gene expression in 
the dorsolateral prefrontal cortex of brain spe-
cimens from patients with schizophrenia and 
bipolar disorder: effect of lifetime intake of an-
tipsychotic drugs. Pharmacogenomics J 2014; 
14: 63-69.
143) Zain MA, Jahan SN, Reynolds GP, Zainal NZ, 
Kanagasundram S, Mohamed Z. Peripheral 
PDLIM5 expression in bipolar disorder and the 
effect of olanzapine administration. BMC Med 
Genet 2012; 13: 91.
144) Fries GR, Bauer IE, Scaini G, Wu MJ, Kazimi IF, 
Valvassori SS, Zunta-Soares G, Walss-Bass C, 
Soares JC, Quevedo J. Accelerated epigenetic 
aging and mitochondrial DNA copy number in bi-
polar disorder. Transl Psychiatry 2017; 7: 1283.
145) Kasahara T, Kato T. What Can Mitochondrial 
DNA Analysis Tell Us About Mood Disorders? 
Biol Psychiatry 2018; 83: 731-738.
146) Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato 
T. Molecular characterization of bipolar disorder 
by comparing gene expression profiles of post-
mortem brains of major mental disorders. Mol 
Psychiatry 2004; 9: 406-416.
147) Kato T, Hayashi-Takagi A, Toyota T, Yoshikawa T, 
Iwamoto K. Gene expression analysis in lympho-
blastoid cells as a potential biomarker of bipolar 
disorder. J Hum Genet 2011; 56: 779-783.
G. Kalcev, A. Preti, A. Scano, G. Orrù, M.G. Carta 
5724
148) De Luca V, Likhodi O, Van Tol HH, Kennedy 
JL, Wong AH. Tryptophan hydroxylase 2 gene 
expression and promoter polymorphisms in bipo-
lar disorder and schizophrenia. Psychopharma-
cology 2005; 183: 378-382.
149) Massat I, Souery D, Del-Favero J, Van Gestel S, 
Serretti A, Macciardi F, Smeraldi E, Kaneva R, 
Adolfsson R, Nylander PO, Blackwood D, Muir 
W, Papadimitriou GN, Dikeos D, Oruc L, Seg-
man RH, Ivezic S, Aschauer H, Ackenheil M, 
Fuchshuber S, Dam H, Jakovljevic M, Peltonen 
L, Hilger C, Hentges F, Staner L, Milanova V, Ja-
zin E, Lerer B, Van Broeckhoven C, Mendlewicz 
J. Positive association of dopamine D2 recep-
tor polymorphism with bipolar affective disorder 
in a European Multicenter Association Study of 
affective disorders. Am J Med Genet 2002; 114: 
177-185.
150) Massat I, Lerer B, Souery D, Blackwood D, Muir 
W, Kaneva R, Nöthen MM, Oruc L, Papadimitriou 
GN, Dikeos D, Serretti A, Bellivier F, Golmard JL, 
Milanova V, Del-Favero J, Van Broeckhoven C, 
Mendlewicz J. HTR2C (cys23ser) polymorphism 
influences early onset in bipolar patients in a lar-
ge European multicenter association study. Mol 
Psychiatry 2007; 12: 797-798.
151) Colasanti A, Owen DR, Grozeva D, Rabiner EA, 
Matthews PM, Craddock N, Young AH. Bipolar 
Disorder is associated with the rs6971 polymor-
phism in the gene encoding 18 kDa Transloca-
tor Protein (TSPO). Psychoneuroendocrinology 
2013; 38: 2826-2829.
